



EGYPTIAN ACADEMIC JOURNAL OF
BIOLOGICAL SCIENCES
ZOOLOGY


B



ISSN
2090-0759

WWW.EAJBS.EG.NET

Vol. 17 No. 1 (2025)



<http://eajbsz.journals.ek.b.eg/>

The Potential Therapeutic Advantages of Using Nanotechnology in the Treatment of Liver Fibrosis: A Review

Hanaa M. Ashqar¹; Abdulkader M. Shaikh Omar^{1&2} and Salim M. El Hamidy^{1&2}

¹Biological Sciences Department, Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.

²Princess Dr. Najla Bint Saud Al-Saud Center for Excellence Research in Biotechnology, King Abdulaziz University, Jeddah, Saudi Arabia.

*E-mail: hashgar@kau.edu.sa; selhamidy@kau.edu.sa

REVIEW INFO

Review History

Received:10/12/2024

Accepted:5/2/2025

Available:9/2/2025

Keywords:

Liver fibrosis,
nanomedicine,
inorganic
nanoparticles,
organic
nanoparticles, drug
delivery,
combination
therapy.

ABSTRACT

Liver fibrosis is a complex medical condition characterized by the abnormal and excessive buildup of extracellular matrix proteins, primarily collagen, in liver tissue, disrupting normal tissue architecture and functionality. This accumulation can lead to various complications and adversely affect the overall health of the involved organs. This pathological phenomenon typically arises from chronic liver injury, often caused by multiple factors. Early detection and intervention are crucial to minimize ongoing liver damage and enhance clinical outcomes for those affected. While significant progress has been made in understanding the molecular pathways involved in liver fibrosis, there remains a strong demand to expand the treatment options available for this condition. The use of nanoparticles (NPs) in combination therapies has gained popularity, leveraging advancements in drug delivery systems. This approach enables the simultaneous administration of several pharmacological agents, thus enhancing therapeutic effectiveness for liver fibrosis and other conditions. Researchers increasingly view NPs as innovative tools capable of optimizing combination therapies through targeted delivery of medications, thereby improving bioavailability and overall therapeutic impact. Recent research in nanotechnology highlights the potential of NP-mediated drug delivery systems to change the treatment landscape for liver fibrosis. Various NP systems, including both inorganic and organic NPs, present innovative avenues for achieving sustained drug release, targeted treatment, and enhanced stability, reducing the likelihood of rapid clearance in infected tissues. This review examines the evolving role of nanotechnology in managing liver fibrosis, summarizing recent findings and assessing various technologies for their effectiveness and potential. We will showcase innovative strategies and significant results while comparing nanoparticle methods to evaluate their efficacy. Furthermore, we will investigate the applications of nanomaterials in drug delivery, targeting, and diagnostics, unveiling the exciting advancements shaping the future of liver fibrosis treatment.

INTRODUCTION

The significance of prioritizing research in nanomedicine and drug delivery systems lies in the ability to create effective therapeutic strategies, especially for conditions like liver fibrosis. This review serves as an essential guide for discovering advanced medical treatments and improving healthcare outcomes, particularly in regions where research is limited, such as Saudi Arabia. The increasing prevalence of liver diseases in the area, including fibrosis and cirrhosis driven by obesity, diabetes, and hepatitis, necessitates

immediate attention. Emphasizing nanotechnology is in line with the Kingdom's Vision 2030, which seeks to promote healthcare research and expand treatment options. Moreover, utilizing nanotechnology could boost the effectiveness of treatments for liver fibrosis, resulting in improved patient outcomes and decreased healthcare.

A-Liver Fibrosis:

Definition and Causes of Liver Fibrosis:

Liver fibrosis represents a significant global health challenge, particularly within the context of chronic liver diseases. This condition frequently arises as a consequence of various long-standing liver disorders, including viral hepatitis, alcoholic liver disease, and non-alcoholic fatty liver disease (NAFLD) (Ballestri *et al.*, 2021).

The liver has a distinctive structure featuring a complex vascular system. It is primarily supplied by the hepatic artery and is associated with two venous systems: the portal and hepatic veins. Additionally, the liver houses the intrahepatic biliary tract, which exits the organ as the common hepatic duct (Ugo *et al.*, 2021). The liver is segmented into polygonal units called lobules, divided by connective tissue. The functions of the liver, which include detoxification, the urea cycle, and the synthesis of plasma proteins, are essential roles fulfilled by hepatocytes. These hepatocytes are organized in linear formations that radiate from the central vein to the periphery of the lobule, creating sinusoids the spaces located between the radially aligned cell arrangements (Zhang *et al.*, 2020).

The hepatic sinusoids exhibit structural and functional characteristics that distinguish them from the capillaries found in other organs. A notable structural feature of the hepatic sinusoids is the absence of a basement membrane, which leads to the development of unique morphological attributes of the hepatic sinusoidal cells, namely liver sinusoidal endothelial cells (LSECs), Kupffer cells (KCs), and hepatic stellate cells (HSCs). LSECs possess fenestrations and sieve plates that facilitate the efficient exchange of substances between the sinusoidal lumen and the space of Disse. HSCs adjacent to LSECs function as sinusoidal pericytes that adhere directly to hepatocytes. These cells remain in a quiescent state through these adhesions, with activation occurring upon their retraction. (Yuasa *et al.*, 2024).

Hepatic stellate cells (HSCs) are mesenchymal cells in the Disse space, located between liver sinusoidal endothelial cells and hepatocytes. These cells feature thorn-like micro-projections known as spines, which extend from their surface to traverse the Disse space, thereby establishing adherens junctions with adjacent hepatocytes. Research has investigated the disruption of adherens junctions between hepatic stellate cells (HSCs) and hepatocytes, identifying this disruption as a catalyst for HSC activation. Cell adhesion molecules are central to the progression of hepatic fibrosis and may serve as potential targets for antifibrotic therapies. Furthermore, integrins and cadherins emerge as critical components in liver fibrosis, suggesting they could represent promising therapeutic targets for treatment strategies (Hintermann and Christen 2019). Furthermore, epithelial cadherin (E-cadherin) has been identified as the adhesion molecule responsible for mediating the connection between hepatocytes and HSCs (Hintermann *et al.*, 2019; Urushima *et al.*, 2021).

Hepatic stellate cells (HSCs) are rich in lipids, a characteristic of a healthy liver. The liver plays a vital role in regulating lipid homeostasis by producing, storing, and releasing lipids, which serve two essential functions in the liver. However, excessive accumulation of lipids within hepatocytes can impair normal liver function. If not managed adequately, this lipid accumulation has the potential to result in hepatic fibrosis, primarily due to the activation of hepatic stellate cells, (Molenaar *et al.*, 2020).

Hepatocytes store limited quantities of neutral lipids within lipid droplets (LDs). Simultaneously, despite constituting less than 8% of the liver's cellular composition, HSCs retain substantial LDs primarily responsible for storing most vitamin A in the human body. When excessive lipid accumulation occurs within hepatocytes, HSCs deplete their significant vitamin A-enriched LDs and undergo a transactivation process into a phenotype characterized by extracellular matrix production, a defining feature of liver fibrosis. Approaches aimed at maintaining HSCs in an LD-rich state while concurrently reducing LD levels in hepatocytes are anticipated to be crucial in preventing or reversing liver fibrosis (Kusumoputro *et al.*, 2023; Molenaar *et al.*, 2020).

Additionally, HSCs are known to store substantial amounts of vitamin A in lipid droplets, which can also store retinoids in lipid vesicles. In specific pathological conditions, these cells may experience a reduction in retinoid content, leading to their transformation into fibroblast-like cells. This phenomenon significantly affects the fibrogenic response (Carmona *et al.*, 2019). In contrast, retinoic acid (RA) functions to activate the retinoic acid receptor (RAR), which is essential for the regulation of fibrogenesis (Delgado *et al.*, 2021; Khomich *et al.*, 2019).

Following this process, fibroblast-like hepatic stellate cells (HSCs) demonstrate an increase in the expression levels of fibroblast activation protein (FAP), which is a type II transmembrane glycoprotein found on the surfaces of activated hepatic stellate cells (aHSC). Consequently, there is an accumulation of extracellular matrix (ECM) components, predominantly collagen. The excessive accumulation of collagen disrupts the normal structural integrity of the liver, resulting in compromised liver function and the development of hepatic fibrosis (Hu *et al.*, 2019; Karsdal *et al.*, 2020).

Hepatic stellate cells (HSCs) are crucial in liver regeneration following injury. These cells synthesize and secrete hepatocyte growth factor (HGF), which interacts with the cMet receptor found on hepatocytes, biliary cells, and endothelial cells. The depletion or inhibition of HSCs negatively impacts the regeneration process. Additionally, genetically inhibiting HSC activation reduces hepatocyte proliferation and worsens liver injury (Acharya *et al.*, 2021).

Furthermore, HSCs contribute to angiogenesis by releasing several growth factors, including platelet-derived growth factor (PDGF), transforming growth factor beta (TGF β), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), and angiopoietin. In the later stages of regeneration, HSCs help reconstruct the basal extracellular matrix and sequester growth factors, as well as prevent their premature activation in hepatocytes. (Kamm *et al.*, 2022; Wiering *et al.*, 2023).

Gaining insight into the molecular mechanisms of fibrosis will help us better understand this biological process and identify possible targets for treatment. As per the findings of Vuppalachchi *et al.*, (2021), the complex nature of liver fibrosis makes it exceptionally challenging to address. However, considering these challenges, ongoing research, development, and focused efforts are underway to overcome these obstacles and achieve better patient outcomes. The discussion revolved around the implications of this knowledge for treating the specific illness. Despite tremendous progress in our comprehension of the subject, much remains to be discovered about the cellular and molecular processes involved in fibrogenesis (Salimi *et al.*, 2022).

Accordingly, Acharya *et al.* (2021) summarized the current understanding of crucial pathways and the cellular and molecular factors contributing to hepatic fibrosis. Given the intricate pathophysiological pathways involved, treating liver fibrosis must be more complex than expected. However, a substantial workforce and material resources have been dedicated to creating effective treatments (Agnihotri *et al.*, 2023).

B. Nanotechnology and its Potential in Medicine:

In recent years, nanotechnology has achieved significant advancements, resulting in the development of specialized nanodevices and nanomaterials that have identified intriguing applications within the medical field (Kim *et al.*, 2020; Li *et al.*, 2022). Health, the economy, the environment, and industry have all been directly impacted by the development of intelligent materials, biosensors, packaging materials, nutraceuticals, and nanodevices, all of which aim to address various medical-related issues (Park *et al.*, 2020; Durán-Lobato *et al.*, 2021).

Nanoparticles (NPs) are materials with dimensions ranging from 1 to 100 nanometres. In biomedicine, these nanoscale systems display unique physicochemical properties, such as their small size, large specific surface area, high reactivity, and quantum effects. These properties make nanoparticles highly suitable for biomedical applications, including drug delivery, imaging, and diagnostic purposes (NPs) (Lin *et al.*, 2023; Zhang *et al.*, 2023).

When particles exceed 100 μm in size, reticuloendothelial system (RES) cells, mainly found in the liver and spleen, efficiently recognize and engulf them for removal from the body. Similarly, particles smaller than 10 nm can be filtered by the kidneys and quickly eliminated through urine. This swift clearance process ensures that both large and

small particles are effectively disposed of, aiding in maintaining the body's homeostasis and overall health (Wang *et al.*, 2021).

In a pursuit characterized by both challenges and achievements, Wang and colleagues (2024) report that nanotechnology is crucial for progress in medicine, especially in nanomedicine, to overcome challenges in treating chronic diseases. The utilization of nanoparticle (NP) systems has become a rapidly advancing field of interest for the secure administration of diverse drugs and nucleic acids in the context of chronic liver diseases. (Surendran *et al.* 2017).

Several NPs have been documented in the last 25 years. However, only a small number have been converted into practical applications. (Ma *et al.*, 2017; Khan *et al.*, 2019; Wang *et al.*, 2021). The promising approach of nanomedicines is demonstrated by the more than 90 approved for clinical use (Thapa and Kim, 2023). Moreover, nanotechnology is gaining increasing significance in liver disease treatment and diagnosis, mainly due to the emergence of novel treatment approaches (Singh *et al.*, 2023).

During the early stages of research, the authorized nanoparticles were primarily utilized for treating liver disorders or infectious diseases since they mainly gathered in the liver or were absorbed by the reticuloendothelial system (RES). Kaps *et al.* (2023) introduced innovative oral tablets that utilize nanoparticle technology, setting a new benchmark in the field of nanoformulation. This approach enhances the medication's effectiveness and revolutionizes how we deliver pharmaceutical compounds, leading to improved patient outcomes and advanced therapeutic possibilities.

Exceptional nanostructures transform liver fibrosis diagnostics, demonstrating capabilities surpassing traditional methods. These structures are active therapeutic agents, improve imaging contrast and function as advanced diagnostics nanoprobes. The benefits of nanoparticles include extended circulation times, better tissue penetration, controlled therapeutic release, enhanced imaging clarity, optimized drug pharmacokinetics, and reduced side effects (Zhang *et al.*, 2020).

This cutting-edge technology is instrumental in pinpointing crucial biomarkers and deepening our understanding of how liver fibrosis progresses. The choice of methodology hinges on the specific characteristics of the medicine being used and the disease it targets. Exploring drug combinations also involves various methodologies, highlighting the need for a comprehensive reference model tailored for all biomedical applications (Vakil and Trappe 2019). The modification and functionalization of nanoparticles (NPs) are essential for realizing their full potential, particularly in biocompatibility, colloidal stability, dispersion, and environmental interactions (Georgilis *et al.*, 2020). Surface functionalization, which entails adding a chemical functional group to the nanoparticle surface, significantly enhances self-organization and compatibility. Moreover, properties such as surface electrical charge, energy, topology, and bioreactivity can be tailored to meet the specific requirements of various applications (Li *et al.*, 2022).

Designing nanoparticles to target (HSCs) encompasses two primary strategies. The first involves the active targeting of HSCs by surface modification of organic nanoparticles to confer specificity to HSCs. The second strategy involves the passive targeting of HSCs through the systemic administration of organic and inorganic nanoparticles that do not rely on specific ligands (Hu *et al.* 2019).

The most common method is surface functionalization through in situ synthesis; ligands like inorganic compounds, polymers, biomolecules, and surfactants allow further surface modification. Surface modification can also be achieved using synthetic approaches involving a range of interactions, including electrostatic, covalent, non-covalent, and intrinsic bonding (Shukla, 2020). These strategies significantly enhance biocompatibility, dispersibility, reactivity, binding capacity, and catalytic activity, making them invaluable for advancing research and applications in the field (Natesan & Kim, 2023).

The anti-inflammatory properties of nanoparticles (NPs) are attributed to their capacity to inhibit the expression of pro-inflammatory cytokines such as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) (Zhou *et al.*, 2020). Furthermore, nanoparticles exhibit antioxidant functionality by obstructing the generation of reactive oxygen species (ROS) produced by substances inducing oxidative stress. Lastly, their pro-oxidant properties are recognized for elevating ROS levels, ultimately contributing to oxidative stress, which in turn triggers apoptosis in the cells of the liver and kidneys.

Consequently, NPs are like a double-edged sword; understanding their toxicity will help refine their inherent therapeutic benefits (Wal *et al.*, 2019; Hashim *et al.*, 2022).

Types of Nanoparticles for Disease Treatment:

Nanoparticles are conventionally categorized into three principal classifications: organic, inorganic, and carbon-based, although the latter may occasionally be amalgamated with the former categories. Organic nanoparticles are synthesized from naturally occurring substances, such as albumin. These nanoparticles present several advantageous characteristics, including enhanced biocompatibility and diminished antigenic effects, particularly pertinent in liposome applications (Ijaz *et al.*, 2020). One method of classifying nanoparticles is distinguishing them into protein, polymeric, metallic, liposomal, lipid-based, and various other structures. The specific application of a nanoparticle largely depends on its structural composition (Zahin *et al.*, 2020).

However, the most distinct types are based on the material they are made from: inorganic, polymeric, lipid-based, bioinspired, and hybrid. Encapsulating hydrophilic pharmaceuticals, such as proteins, has enhanced stability under biological conditions and improved transmission across cell membranes and the bloodstream (Yin and Zhong 2020).

Inorganic Nanoparticles (INPs):

Typical representatives of the inorganic category include metals and metal oxides. Nanomaterials possess unique physical and chemical properties that can be tailored to fulfil specific objectives in drug delivery systems (Namiot *et al.*, 2023). Metal nanoparticles are tiny particles measuring 0 to 100 nm in size. Materials in this category consist of pure metals, including gold and silver, or metal oxides, such as cerium, iron, and zinc (Boey and Ho 2020). Metallic nanoparticles can take on various shapes, such as spheres, rods, and tubes. These features, such as surface area, charge, solubility, and stickiness, can change their physiochemical properties and biochemical fate (Khan *et al.*, 2019).

Metallic inorganic nanoparticles (INPs), specifically nanomaterials, can systematically release drugs and effectively infiltrate tissues at greater depths. This feature makes them a promising option for creating highly targeted and efficient drug delivery systems (Park *et al.*, 2020). Numerous nanoparticles have been utilized to treat liver fibrosis or chronic liver disease, including Fibroblast growth factor 2 conjugated superparamagnetic iron oxide nanoparticles (FGF2-SPIONs), silymarin-conjugated gold nanoparticles (SG-NPs), and cerium oxide nanoparticles (Ce-NPs) (Kurniawan *et al.*, 2020; Abdullah *et al.*, 2021; Flores-Rojas *et al.*, 2022; Lebda *et al.*, 2022).

• Gold Nanoparticles (Au-NPs):

Gold nanoparticles (Au-NPs) are a commonly utilized nanocarrier for delivering therapeutic oligonucleotides (TOs) to specific targets (Debacker *et al.*, 2020; Wu *et al.*, 2022). They demonstrated that utilizing curcumin as a reducing agent and cetyltrimethylammonium bromide as a stabilizing agent enhances the production of Au-NPs at various pH levels. The creation of gold nanoparticles was confirmed by observing the color change in the solution. Regardless of the method used to create the nanoparticles, curcumin improves the effectiveness of the Au-NPs, which exhibit favorable characteristics for biomedical uses.

Commercial Blu-ray discs incorporate large nanostructured arrays used to create gold-coated nanoplasmonic surfaces. In a 2D fatty liver disease model, gold nanograting measured albumin and optimal fetal bovine serum (FBS) concentrations to enhance lipid levels in treated cells. Furthermore, fat exposure reduces hepatocyte viability and metabolism, increasing lipid accumulation (Lopez-Muñoz *et al.*, 2020).

Ribera's research (2021) has demonstrated that platelet-derived growth factor (PDGF) and its receptor β (PDGFR β) play a critical role in the activation of hepatic stellate cells. These components may represent viable targets for the development of anti-fibrotic therapies. A new method employs plasmonic photothermal treatment using gold nanorods coated with polyethylene glycol and conjugated with PDGF and PDGFR β antibodies. This therapy specifically targets activated hepatic stellate cells, reducing fibrosis, inflammation, and liver damage, therefore preventing accumulation in the liver.

A study investigated nanoparticles with natural compounds and fruit extracts. Gold nanoparticles capped with polyphenols from *Cornus sanguinea* (NPCS) were combined with blueberry extract (VL) to form NPCS-VL. This hybrid was tested on human hepatic stellate cells (LX-2) exposed to TGF- β . Results showed NPCS-VL reduced membrane

damage and inflammation but increased collagen III expression, indicating a fibrogenic effect. VL lowered LDH activity and pro-inflammatory cytokine release. NPCS alleviated TGF- β -induced inflammation and downregulated α -SMA. Thus, combining fruit extracts and gold nanoparticles may effectively lower collagen I synthesis and reduce fibrosis severity (Filip *et al.*, 2023).

Conversely, the findings by Alshammari *et al.* (2023) indicate that contamination with AuNPs during Doxorubicin therapy can lead to significant hepatic toxicity and steatosis in rats. The findings suggest that gold nanoparticles (AuNPs) and doxorubicin (DOX) may work synergistically to exacerbate liver damage and steatosis by upregulating various lipid-related lipogenic genes and inflammatory mediators while concurrently inhibiting their functional activity.

•Silver Nanoparticles (Ag-NPs):

H. Zhang *et al.* (2019) conducted a study regarding liver injury induced by carbon tetrachloride (CCl₄) in mouse models. Investigators examined how *Rhizophora apiculata*-synthesized silver nanoparticles protected the livers of experimental mice from hepatotoxins. Assessment findings show silver nanoparticles effectively protected the liver from carbon tetrachloride-induced damage. Based on the existing literature, they concluded that this is the first method for assessing the hepatoprotective effects of nanoparticles from plant extracts found in mangrove ecosystems.

In another experiment, Teng *et al.* (2019) developed silver nanoparticles (Ag-NPs) using a non-toxic dose that does not induce overall toxicity in healthy mice. Later, it was reported that Ag⁺ ions were reduced to form Ag-NPs in fatty livers. The harmful effect of this nanoformulation was linked to the concentration of silver nanoparticles (Ag-NPs) in the liver rather than silver ions (Ag⁺). Ag-NPs increased hepatic inflammation by stimulating Kupffer cells in the liver and inhibiting fatty acid oxidation. Sameem *et al.* (2022) focused on silver nanoparticle biosynthesis. The nanoformulation has been developed to contain a high concentration of essential biomolecules found in *Ziziphus mauritiana* extract, successfully reducing oxidative stress and inhibiting liver cell damage.

Besides, concurrent administration of Ag-NPs coated with curcumin and chitosan inhibited the progression of liver fibrosis. In its nano form, Curcumin was discovered to be an effective medication against liver fibrosis. It maintains the structure and function of the liver intact as the condition progresses. This effectiveness is due to its inhibitory function, achieved by directly interacting with proteins mediating fibrosis, like PDGFRB, TIMP-1, TLR-9, and TGF- β . (Elzoheiry *et al.*, 2022).

Conversely, research conducted by Ziaolhagh *et al.* (2023) concentrated on evaluating the resistance of hepatocytes to chemicals compared to biological silver nanoparticles when subject to aerobic and anaerobic pre-conditioning during rodent treadmill training. Histopathological findings revealed that injecting nano-silver impacts the liver structure of male Wistar rats, leading to inflammation, hyperemia, and liver cell damage, particularly with chemical nano-silver. The study's findings suggest that chemical silver nanoparticles are more damaging to the liver than their biological counterparts. Furthermore, physical pre-conditioning enhances the resistance of hepatocytes to toxic nanoparticle doses, with aerobic preparation proving more beneficial than anaerobic.

Furthermore, Yousof *et al.* (2022) research explores how daily low-dose silver nanoparticles (Ag-NPs) influence liver structure and function in rats. The findings indicate that Ag-NPs induce hepatotoxicity in rats, resulting in elevated liver enzymes and hydrogen peroxide levels. Notably, the toxic effects continued even after ceasing exposure to Ag-NPs. Furthermore, the research indicates that prolonged exposure to Ag-NPs may result in permanent hepatotoxic injury, impairing the liver's natural capacity for rapid regeneration.

Al-Doaiss *et al.* (2020) study also examined the microscopic changes in the liver caused by small-sized silver nanoparticles (Ag NPs) measuring 10 nm, which are increasingly used in medical and industrial applications. The histological, histochemical, and ultrastructural alterations observed in the livers of mice exposed to 10 nm Ag NPs revealed significant damage, including hyperplasia of Kupffer cells, sinusoidal dilation, apoptosis, and glycogen depletion.

In addition, smaller Ag-NpS particles were examined, measured at 10 and 75 nanometers, and larger Ag-NPL particles ranged from 250 to 300 nanometres (Elfaky *et al.*, 2022). The researchers determined that the larger particles could elicit a comparable

pharmacological response, thereby indicating a potentially safer alternative to the smaller silver nanoparticles, which are recognized for their elevated toxicity and propensity to precipitate within liver tissues. Salama *et al.* (2022) research explored the effects of AgNPs on oxidative stress in liver and kidney tissues. Thymoquinone (TQ) was given alongside AgNPs, alleviating this stress by lowering malondialdehyde (MDA) and nitric oxide (NO) levels while raising glutathione (GSH) levels. AgNPs were found to inhibit multiple antioxidant enzymes, such as superoxide dismutase and catalase, but treatment with TQ reinstated their functionality activity.

Additionally, zinc oxide nanoparticles (Zn-NPs) mitigated the histopathological and immunohistochemical changes caused by Ag-NPs. When administered together, Zn-NPs and Ag-NPs diminished oxidative stress, inflammation, and apoptosis while simultaneously enhancing the histological structure of liver and kidney tissues due to their antioxidative effects. Zn-NPs lowered the levels of inflammatory cytokines, oxidative stress, and lipid peroxidation in both hepatic and renal tissues (Shehata *et al.*, 2022).

• Cerium Oxide Nanoparticles (CeO₂-NPs):

Cerium oxide nanoparticles (CeO₂NPs) are gaining recognition as effective antioxidants with therapeutic benefits in experimental liver disease. Their varied biological activities and unique physicochemical characteristics render them suitable for biomedical applications. The properties of CeO₂NPs, such as their shape, size, and surface coatings, significantly influence their behavior inside the body. The size of the particles is particularly crucial in determining how cells uptake them and their activity. Smaller particles (<30 nm) have a higher percentage of Ce³⁺ valence status. CeO₂NPs serve as carriers for focused drug and gene delivery, and their distinct physical and chemical properties allow for easy detection with biomedical imaging methods (Attia *et al.*, 2022).

The antioxidant and enzyme-like properties of CeO₂NPs are well-documented. These nanoparticles have been shown to function as scavengers for reactive oxygen species (ROS) and reactive nitrogen species (RNS) and exhibit mimetic activities akin to superoxide dismutase (SOD), catalase, and peroxidase. These qualities include scavenging reactive oxygen species (ROS) and reactive nitrogen species (RNS), converting hydrogen peroxide into oxygen and water via catalase, and reducing hydroxyl radicals from hydrogen peroxide with peroxidase (Casals *et al.*, 2021).

CeO₂NPs feature numerous oxygen vacancy defects on their surface, rendering them effective for addressing disorders linked to reactive oxygen species (ROS). The formation of oxygen vacancies and electron transitions between Ce⁴⁺ and Ce³⁺ are the main factors determining CeO₂'s catalytic properties, which have attracted interest in biomedical research. Oxygen vacancies and electron transitions between oxidation and reduction states are the main factors influencing CeO₂'s catalytic properties (Beyene *et al.*, 2021; Han *et al.*, 2022).

The hepatoprotective approach of CeO₂-NPs was investigated in an experiment by Adebayo *et al.* (2020) in male mice given diethylnitrosamine (DEN). Diethylnitrosamine injection in mice induced hepatic oxidative stress due to imbalances in oxidants/antioxidants and pro-inflammatory enzymes and inhibited apoptosis. CeO₂-NPs mitigated these effects by enhancing antioxidant enzyme activity and reducing inflammatory and anti-apoptotic proteins. In conclusion, CeO₂-NPs protect the liver from oxidative damage at the tested dosages. In their study, Córdoba-Jover *et al.* (2019) were the first to report that CeO₂NPs promote in rat models of partial hepatectomy and drug-induced liver injury caused by acetaminophen (APAP) overdose. In their investigation of APAP metabolism in the rat liver, the researchers observed a significant increase in transaminase levels two days after APAP administration, with similar effects seen in both the vehicle and CeO₂NPs-treated groups.

The investigation of Carvajal *et al.* (2019) also revealed similar outcomes. Their research paves the way for future applications of CeO₂-NPs in human liver illnesses by demonstrating that these nanoparticles directly shield hepatocytes obtained from humans from reducing oxidative stress by preventing the production of reactive oxygen species (ROS) and reducing inflammatory expression genes. It has also been found that cells subjected to oxidative stress can be treated with CeO₂-NPs, which downregulates specific cell kinase-mediated signaling pathways.

Moreover, the protective effect of cerium oxide nanoparticles (CeO₂NPs) on

thioacetamide (TAA)-induced hepatorenal injuries in rats was investigated. Bashandy *et al.*'s (2022) study found that CeO₂NPs improved antioxidant status, moderated the decrease in plasma catalase, total antioxidant capacity, and hepatorenal ATP content, and reduced the rise in plasma liver enzymes, kidney function markers, and inflammation levels markers. The study's key findings are that CeO₂NPs minimize oxidative stress, inflammation, and hepatorenal pathology induced by TAA and improve liver and kidney function.

From another viewpoint, Boey and colleagues conducted a study on the impact of CeO₂NPs on liver fibrosis using the human-cultured HSC cell line LX2. The study showed that the 25 nm cubic CeO₂-NP effectively prevented fibrosis in LX2 cells activated by TGF- β , primarily by decreasing oxidative stress and TGF- β signaling. This led to decreased HSC activation and, consequently, liver fibrosis. These results indicate a potential role for CeO₂ NP in treating liver fibrosis (Boey *et al.* 2021).

• **Iron Oxide Nanoparticles** IONPs (Fe₂O₃):

In the field of regenerative medicine, iron oxide nanoparticles (IONPs) serve as cell-tracking tracers, among other techniques. Investigating and applying cells for therapeutic purposes constitutes a novel strategy for managing several illnesses (Rahman, 2023). Huang *et al.* (2021) discovered that IONPs of various sizes, shapes, magnetic characteristics, and surface coatings can significantly enhance mitochondrial transfer between cells. This allows for a broadly applicable strategy for human mesenchymal stem cell bioengineering.

Iron oxide nanoparticles are typically coated with a biocompatible substance either during or after their preparation synthesis. This ensures that the SPION remains stable in biological media, protects them from oxidation, makes them more biocompatible, and allows them to attach functional molecules like medicines or targeting ligands (Dadfar *et al.*, 2019).

The dimensions of iron oxide nanoparticles (IONPs) differ depending on their production method and coating. These particles can range from under 50 nanometers to over 100 nanometers. Saraswathy *et al.* (2021) undertook research aimed at creating and assessing a novel iron oxide-based MR contrast agent tailored for the early identification of liver fibrosis and exploring its therapeutic potential. They developed a dual-function, biocompatible nanoprobe, pullulan-stabilized iron oxide nanoparticles (P-SPIONs), suitable for liver-specific diagnostics and treatments, which allows for high specificity in liver imaging, effective hyperthermia, and targeted dual imaging in models of liver fibrosis.

Small heterogeneous iron oxide/dysprosium oxide nanoparticles (IO-DyO-NPs) were developed as a contrast agent for MRI to precisely assess liver fibrosis in living organisms (Fernández-Barahona *et al.*, 2020). Moreover, Balachandran *et al.*'s (2022) findings show robust magnetic resonance imaging (MRI) signals, accurately categorize the liver tissues affected by fibrosis and distinguish between mild and severe cases of clinically relevant conditions. The biocompatible IO-DyO-NPs CAs promote initial fibrosis recognition, which is advantageous due to MRI's noninvasiveness and lack of radiation.

Zhu *et al.* (2021) investigated the effects of COOH-IONPs and NH₂-IONPs on NAFLD in vitro and in vivo. The research indicated that IONP exposure notably exacerbated hepatic steatosis and led to liver damage in NAFLD models. Mice administered IONPs displayed considerable liver injury, as evidenced by increased plasma levels of ALT, AST, and TG, alongside a higher hepatic TG content and more severe hepatic steatosis in H&E staining. These results suggest that iron overload from IONPs in the liver is linked to hepatic inflammation and accelerates the progression from steatosis to steatohepatitis. This aligns with another study conducted by (Kanamori *et al.* 2021).

• **Zinc Oxide Nanoparticles** (ZnO-NPs):

Zinc is a fundamental mineral that is mineralized in several tissues, including the muscles, brain, skin, and bones. It is essential in various processes, including hematopoiesis, neurogenesis, protein and macromolecule synthesis, and most enzyme systems. ZnO has several potential uses. Nonmaterial ZnO has several desirable qualities, including biodegradability and low toxicity.

Thanks to its OH groups, numerous surface-decorating compounds can functionalize ZnO. The odorless, white, and insoluble zinc oxide nanoparticles, or ZnO-NPs, are not soluble in water or alcohol. The unique semiconducting, piezoelectric, and optical characteristics of nano-ZnO, combined with its small particle size, enable quick

absorption by the body (Deka *et al.*, 2022). Furthermore, ZnO-NPs can induce apoptosis and generate reactive oxygen species (ROS) in cells (Afzal *et al.*, 2020).

Since ZnO is safe to use, it is Generally Recognized as Safe "GRAS" material by the US Food and Drug Administration (FDA) since ZnO nanoparticles >100 nm are considered biocompatible (Bilensoy and Varan 2023). Therefore, ZnO-NPs have already been helpful in some fields, including healthcare, commerce, food production, agriculture, and electronics, with most of these applications being deemed safe (Krauss *et al.*, 2019). Production methods can cause ZnO-NPs to exhibit various physicochemical properties. These unique physicochemical features influence the biological activity of ZnO-NPs both in vitro and in vivo applications. The performance of synthetic ZnO-NPs improves by forming hierarchically porous network structures or one-, two-, or three-dimensional structures (Jin and Jin 2019).

Researchers conducted a study to determine the preventive impact of zinc oxide nanoparticles on liver damage, fibrosis, and oxidative stress, attributing it to their diverse pharmacological features, such as anti-diabetic, anti-inflammatory, and antioxidant activities. (Moatamed *et al.*, 2019; Keerthana & Kumar, 2020; Mandal *et al.*, 2022).

Comprehensive histopathological and immunohistochemical research has shown that ZnO nanoparticles provide considerable protection for liver biochemistry. The findings indicate that ZnO nanoparticles effectively protect against detrimental biochemical alterations in the liver (Bashandy *et al.*, 2018).

Rajeshkumar and Sandhiya (2020) Summarized biosynthetic processes for zinc oxide nanoparticles, including methods using plants, bacteria, and algae. These biomolecule-enriched materials effectively reduce metals, highlighting a key mechanism in producing zinc oxide nanoparticles under various conditions. Biological techniques assess the efficacy of newly developed zinc oxide nanoparticles. Experimental methods like X-ray diffraction (XRD), scanning electron microscopy (SEM), and Fourier transform infrared (FT-IR) are used to analyze the size and functionality of the nanoparticle groups.

The biological and environmental remediation potential of biogenic ZnO nanoparticles has prompted substantial research into these materials (Sportelli *et al.*, 2022). Because of this, ZnO-NPs have recently been evaluated by Prasad *et al.* (2021). They have focused on biogenic ZnO-NPs for their possible biological applications; synthesizing NPs with controlled particle size, shape, crystallinity, and other features has been a significant objective in materials science. Singh *et al.* (2020) produced zinc oxide nanoparticles (ZnONPCS) with casein as a reducing and capping agent by a biogenic approach. They created a bio-nanoconjugate (ZnONPCS–Cur) by surface loading curcumin through surface activation. Green synthesis of ZnO-NPs, called Cur-ZnO-NPs, was accomplished with an ethanolic extract of *Curcuma longa* (Agarwal, Nakara, and Shanmugam 2019; El-Kattan *et al.* 2022). The mean particle sizes, with a spherical shape, were around 20 ± 5 nm for Cur-ZnO-NPs. Casein was used as both a reduction and coating agent in a biogenic approach developed by Somu and Paul (2019) to create zinc oxide nanoparticles (ZnO-NPCS). The researchers then used surface activation to establish a bio-nanoconjugates of these nanoparticles with curcumin (ZnO-NPCS–Cur). The green-synthesized Cur-ZnO-NPs demonstrated superior biocompatibility (Perera *et al.*, 2020).

Furthermore, the enhanced therapeutic and protective effects of zinc-curcumin complexes were reviewed. Conjugates of zinc and curcumin have shown improved antioxidant and anti-inflammatory capabilities. Additionally, zinc-curcumin complexes have shown hepatoprotective activity. Decreased inflammatory cytokines, enhanced antioxidant enzymes, reduced free radicals, and triggered apoptotic markers were among several molecular pathways linked to zinc-curcumin conjugates' preventive and therapeutic efficacies (Prasad and Lall, 2022).

Organic Nanoparticles:

Recently, there has been an increasing interest in nanoparticle (NP)-mediated drug delivery systems as potential treatments for various diseases. These systems have several advantages over conventional drug delivery techniques, including liposomal-NPs, polymeric-NPs, and nanocrystals (Li *et al.*, 2024).

Polymer-Based Nanoparticles:

Polymeric nanoparticles (P-NPs) are small polymeric particles with a core that can be filled with active chemicals either by entrapping them within or by adsorption onto their

surface. The umbrella term "nanoparticle" describes nanocapsules and nanospheres based on their morphology (Zielinska *et al.*, 2020). In addition, polymer materials undergo functionalization with biocompatible molecules, including proteins, to significantly enhance their biointegration properties. This process aims to promote better interactions between the polymer surface and biological systems, thereby improving the overall compatibility of the material within a biological environment. (Kittel *et al.*, 2022).

Despite its good toxicity profile, the FDA approved only 19 medication formulations based on Polylactic-Co-Glycolic Acid (PLGA) until 2019. Park *et al.* (2019) state that these formulations comprise solid implants, in situ gels, and PLGA microparticles; none are PLGA NP formulations. This observation suggests difficulties, such as low drug release kinetics and drug entrapment efficiency from PLGA nanoformulations (Chiu *et al.*, 2021). According to recent research, vitamin A (VA) can be used with polymer-based nanoparticles (NPs) to target hepatic stellate cells (HSCs) in the treatment of liver fibrosis. The methodology for conjugating retinol to poly (lactic-co-glycolic acid)-poly (ethylene glycol)-maleimide (PLGA-PEG-Mal) nano-drug delivery systems is elaborated to treat liver fibrosis through the targeted delivery to hepatic stellate cells (HSCs) (Fan *et al.*, 2020).

Lipid-Based Nanoparticles (LNPs):

Researchers in both the preclinical and clinical stages are very interested in lipid-based nanoparticles (LNPs) due to their impressive pharmacological performance and potential therapeutic benefits. The primary physicochemical characteristics and therapeutic potential of the various forms of lipid nanoparticles (LNPs) utilized in drug formulations are introduced by (Kumar *et al.*, 2022; Mehta *et al.*, 2023). The types of LNPs comprise liposomes, nano-emulsions, solid lipid nanoparticles, nanostructured lipid carriers, and lipid-polymer hybrid nanoparticles (Lu *et al.*, 2021).

Lipid-based nanocarriers provide several benefits for delivering peptides and proteins orally. They protect therapeutic peptides and proteins from enzymatic degradation and unwanted thiol/disulfide exchange reactions. Furthermore, these nanocarriers increase the lipophilicity of therapeutic agents and enhance drug permeability through the absorption membrane. Due to their lipophilic characteristics, gastrointestinal peptidases and sulfhydryl compounds, such as glutathione and dietary proteins, cannot penetrate these carriers. This effectively protects therapeutic peptides and proteins from enzymatic degradation and prevents unintentional thiol/disulfide exchange reactions. A comprehensive understanding of the behavior of lipid nanoparticles (LNPs) at the absorption membrane will facilitate the advancement of more effective delivery methods. In summary, LNPs are poised to significantly impact oral peptide and protein therapeutics' administration (Plaza-Oliver *et al.*, 2021; Haddadzadegan *et al.*, 2022;). Jampilek and Kralova (2020) review the latest research on nanoformulation-processed nutraceuticals and their potential benefits for community health. Tulbah and Lee (2021) also discuss various types of LNPs, including liposomes, solid lipid nanoparticles, nanostructured lipid carriers, and nano-emulsions. Agame-Lagunes *et al.* (2021) have examined the therapeutic effects of curcumin (*Curcuma longa*) in nano-emulsions stabilized by medium-chain fatty acids. This nanosystem enhanced curcumin's bioactivity and the need for large drug concentrations, preventing possible adverse effects.

The properties of nanoparticles (NPs) can be customized to enhance their accumulation in tissues such as the liver and spleen, which are primary sites for generating immunological antigens. Implementing immune-recruiting systems, such as polymeric hydrogels and scaffolds, can enhance interactions with antigen-presenting cells (APCs), thereby contributing to the modulation of immune responses (Mitchell *et al.*, 2021).

• Liposomes:

Lipid nanoparticles have become a favored option for simultaneously delivering drugs because of their outstanding capacity to enclose various therapeutic agents. Liposomes can vary in size and form unilamellar or multilamellar structures (Kumar, 2019). Their membranes are made of two layers of phospholipids, and they can be loaded with drugs. These carriers are highly efficient and biocompatible, making them ideal for drug delivery applications (Patel 2020).

Liposome-mediated drug delivery systems (LDDS) are the most widely employed multifunctional carriers in treating liver fibrosis (Xiao *et al.*, 2018; He *et al.*, 2019; Antimisiaris *et al.*, 2021; Lee *et al.*, 2023). These systems are designed to address

hyperproliferation and anti-apoptosis issues, thereby improving the efficacy of liver disease therapeutic drugs (Cheng *et al.*, 2023). It has been reported that these LDDS have demonstrated their effectiveness in delivering drugs for disease treatment since they exhibit the advantage of being nano-sized carriers, which involves targeting liver cells while minimizing harm to healthy cells (Li *et al.*, 2024). For example, scientists propose various methods to improve curcumin's bioavailability. Among these methods is the utilization of enhancers, which involve combining curcumin with phospholipids or incorporating it into nanoparticles or liposomes (Smirnova *et al.*, 2023).

• Micelles:

Nanomicelles are nano-sized colloidal dispersions that self-assemble and have a hydrophobic core and hydrophilic shell. Due to their size, solubility, customized surface, and environmental exposure, nanomicelles exhibit unique and novel characteristics, making them multifunctional and essential for use in biomedical applications and other fields. They are guided to a particular spot on the body through ligand-receptor interactions and the attachment of targeting ligands. They may overcome many difficulties traditional pharmacotherapy could not conquer (Nel, 2020; Bose *et al.*, 2021; Huang *et al.*, 2024).

According to Zhao *et al.* (2023), liver sinusoidal endothelial cells (LSECs) play a crucial role in absorbing and metabolizing more than 90% of hyaluronic acid (HA), a natural ligand and encapsulated micelle known for its prolonged drug release and low cytotoxicity when directed at LSECs. A study led by Mar Gil and colleagues (2023) focused on improving the delivery of statins to liver cells. The researchers optimized a delivery system using polymeric micelles and peptide ligands to release simvastatin gradually. This could aid in preserving the specialized phenotype of liver cells and maintaining liver function.

Due to specific targeting, for example, the concentration of the drug is increased within the target cell or tissue while reducing adverse effects on other cell types (Gu *et al.*, 2022). Accordingly, Radwan *et al.* (2020) designed and optimized reverse micelle-loaded lipid nanocapsules (RMLNC), aiming to suppress hepatic fibrosis progression by targeting activated hepatic stellate cells (aHSCs) via increased cellular uptake and anti-fibrotic activities.

Micelles that target hepatic macrophages have been suggested for treating liver disorders (Colino *et al.*, 2020). The liver macrophages' preference for liposome absorption makes them ideal for delivering anti-inflammatory, anti-infective, or other medications to treat liver disorders. Combined with anti-inflammatory drugs, they can improve the regulatory status of macrophages and lower the dosage needed to treat acute and chronic liver injury (Dong *et al.*, 2019; Cheng *et al.*, 2021; Martínez-Sánchez *et al.*, 2023).

C-Applications of Nanotechnology in Disease Treatment:

a) Drug Delivery Systems:

Medication combinations may be the most effective course of treatment without more advanced biopharmaceutical delivery methods (Bondarenko *et al.*, 2021). Combining medications can lead to additive, synergistic, or antagonistic effects, resulting in reactions that are the same, increased, or decreased compared to taking them separately. Using multiple drugs that function together within complex biological networks is crucial to achieving a synergistic effect rather than targeting a specific area alone. This collaborative approach ensures the medicines work harmoniously, maximizing their strengths for a more effective treatment outcome (Yuan and Chen 2019).

Multiple medications enable the biological network to be targeted at various points, thus mitigating the possibility of resistance to the treatment by the network. Therefore, employing a synergistic approach is instrumental in achieving optimal treatment outcomes (Wang & Huang, 2020). Each compound presents unique pharmacokinetic characteristics for free drugs and is metabolized at varying rates. Consequently, when administering synergistic combinations of free drugs to target cells, it is essential to account for and mitigate the effects of these pharmacokinetic processes (Anselmo and Mitragotri 2019).

Combination therapy is becoming increasingly integral to advancing medical treatments and improving patient outcomes, as it enhances treatment outcomes and substantially increases patient survival rates. This robust approach amalgamates various treatment modalities, resulting in improved results and greater optimism for individuals

confronting health challenges (Keservani *et al.*, 2020; Peng *et al.*, 2021).

One of the main advantages of NP-mediated drug delivery is its ability to provide targeted drug delivery, which means that drugs can be delivered directly to the site of infection or disease without affecting healthy tissues (Sharma *et al.*, 2019). In addition, these systems can also provide extended drug release, which ensures that drugs are released gradually over a more extended period, thus improving their efficacy and reducing the need for frequent dosing (Zhang *et al.* 2019). The drug-delivering-drug (DDD) platform is an innovative procedure that enables the concurrent administration of a secondary drug alongside insoluble drugs, utilizing drug crystals as a carrier (Du *et al.* 2021).

The delivery of drugs through nanoparticles is a promising technique that has the potential to enhance the stability and effectiveness of medication. By preventing drugs from being rapidly cleared at the site of infection or disease, they remain active for longer, improving therapeutic outcomes for various diseases (Pathak *et al.*, 2019). Nanoparticle-mediated drug delivery systems possess distinctive characteristics, including elevated biocompatibility, adaptability, and target selectivity, rendering them up-and-coming contenders for drug development (Park *et al.*, 2022). By precisely delivering therapeutics to specific cells, tissues, and organs, nanoparticle-mediated drug delivery systems can reduce off-target effects and minimize the required drug doses, making treatments more effective and safer (Nag and Delehanty, 2023).

Many new ways of preparing herbal drugs as particles, such as liposomes, nanoparticles (NPs), micelles, nano-suspensions, nano-capsulation, nano-emulsions, and more, can be used to make drug delivery systems (DDSs) more effective at targeting receptors on HSCs, hepatocytes, macrophages, and other cells (Xiao *et al.*, 2018; Devaraj & Rajeshkumar, 2020; Castro-Pastrana *et al.*, 2021; Saadh, 2021; Haddadzadegan *et al.*, 2022; Ibrahimiyah *et al.*, 2023). Fan *et al.* (2019) created a polymeric micelle (CRM) featuring a co-decorated surface of collagenase I and retinol to demonstrate this mechanism. This design allows it to break down pericellular collagen I and target HSCs. Human HSCs effectively took up the CRM and showed remarkable accumulation in the fibrotic liver, indicating its promise as a delivery system for drugs aimed at liver fibrosis. Additionally, they developed a CRM loaded with nilotinib (CRM/NIL), which displayed optimal antifibrotic activity and a favorable toxicity profile, highlighting its potential in liver fibrosis treatment. This method enhances co-delivery and is particularly useful for delivering biopharmaceuticals and small molecular-weight compounds (Du *et al.*, 2021; Teng *et al.*, 2022).

To effectively target the liver following systemic administration, utilizing particles smaller than 100 nm is essential. This size is critical as only such nanoparticles can successfully navigate through the liver fenestrae to access hepatocytes and hepatic stellate cells (Younis *et al.* 2021). The fenestrae function as selective filters, regulating the movement of solutions, solutes, and particles between the sinusoidal lumen and the space of Disse. They exclusively facilitate the transit of particles that are smaller than the fenestrae, thereby enabling the delivery of these particles to the parenchymal cells or their removal from the space of Disse. These dynamic structures are aggregated into sieve plates that function as regulatory gatekeepers, controlling the passage of fluids, solutes, and macromolecules between the sinusoid and the space of Disse (Zapotoczny *et al.*, 2019; Gracia-Sancho *et al.*, 2021).

When NPs are utilized as drug delivery systems, they have the potential to stimulate several immune pathways simultaneously (Liu *et al.*, 2019; Thorp *et al.*, 2020). By doing so, NPs can enhance the effectiveness of the drug treatment, as they can target multiple aspects of the immune system at once (López-Saucedo *et al.*, 2018). This is particularly beneficial in medical contexts as eliciting a broad immune response to combat disease or infection or improving the delivery efficiency and reducing side effects is desirable (Q. Hu *et al.*, 2019; Jacob *et al.*, 2023; Kusumoputro *et al.*, 2023; Li *et al.*, 2023).

Furthermore, nanoparticle-mediated delivery systems offer vital benefits, primarily improved targeting for precise therapeutics delivery. This method minimizes harm to healthy tissues while enhancing efficacy. Additionally, these systems support therapy via various routes, including intravenous, oral, or localized methods. Meeting individual patient needs, they address clinical demands and enhance treatment outcomes (Li *et al.*, 2024).

Unlike the other methods, drug delivery through nanoparticles allows precise drug delivery to fibrotic areas and controlled release, which may lessen the adverse effects on the whole body. In any case, targeted therapy with dual-ligand nanoparticles improves the healing effects of anti-fibrotic drugs (Kumar *et al.*, 2021). Diagnostic nanoprobe, like MRI-based probes, provide helpful information about how diseases progress and how gene therapy uses nanocarriers to go after the genes that cause fibrosis (Sehl *et al.*, 2020; Murar *et al.*, 2022).

Developing targeted nanocarriers incorporating multiple pharmacological agents presents a promising strategy for addressing liver fibrosis. This research focuses on integrating various therapeutic agents into a single nanocarrier system to enhance treatment efficacy. Recent advancements in active targeting strategies for hepatic fibrosis have predominantly concentrated on exploiting hepatic stellate cells (HSCs) as specific targets. However, there is a need for more comprehensive research that incorporates a broader array of ligands to effectively target other liver cell populations (Setyawati *et al.*, 2024).

Chen *et al.* (2019) highlighted HSC-specific markers that may be leveraged for the targeted delivery of antifibrotic agents to the fibrotic liver. Activated hepatic stellate cells (aHSCs) demonstrate significant overexpression of various protein markers, including the type VI collagen receptor, retinol-binding protein receptor (RBP-R), platelet-derived growth factor receptors (PDGF-R), synaptophysin (p38), insulin-like growth factor II receptor (IGFII-R), low-density lipoprotein receptor (LDL-R), and cluster of differentiation 44 (CD44). These markers provide potential targets for the selective delivery of antifibrotic therapies to activated HSCs, enabling more precise treatment strategies in fibrosis management (Chen *et al.*, 2019).

Zhang *et al.* (2024) stated that the interplay among capillaries, liver sinusoidal endothelial cells (LSECs), activated hepatic stellate cells (HSCs), and defective hepatocytes creates a vicious cycle in developing liver fibrosis. This vicious cycle exaggerates the disease and reduces the effectiveness of any therapy. To inhibit the malicious progression of liver fibrosis, they offer a potential new direction for developing anti-fibrotic treatments, emphasize the need to regulate cellular interaction, and propose a vicious cycle-breaking approach that independently targets and repairs diseased cells.

Additionally, nanosystems for vaccine delivery are advancing rapidly in their development. 2023, a quantitative analysis was performed on clinical trials involving nanoparticles between 2016 and 2021. The study aimed to elucidate emerging trends in nanoparticle research, focusing on their applications in treating COVID-19. Additionally, the findings were compared against existing literature reviews to identify advancements and gaps in the current knowledge base. Both polymeric and liposomal nanoparticles serve as effective carriers and adjuvants. Furthermore, lipid-based nanoparticles were utilized in two of the most widely administered COVID-19 vaccines Moderna and Pfizer-BioNTech (Namiot *et al.*, 2023).

b) Gene Therapy and Editing:

Research has demonstrated various strategies for inducing anti-fibrotic effects, particularly in treating liver fibrosis. One notable approach involves using Relaxin, which explicitly targets hepatic macrophages. Research conducted by Hu *et al.* (2021) demonstrated that gene therapy utilizing Relaxin effectively eradicated fibrosis, highlighting this approach's therapeutic potential in managing liver fibrosis.

To better understand the reasons behind the variations in gene expression of transmitted genes, a study by Kimura and Harashima (2023) analyzes two distinct types of lipid nanoparticles (LNPs): those that target the liver selectively and those that are more spleen-selective. The findings suggest that variations in gene expression effectiveness are influenced more by endogenous factors than by the extent of biodistribution across tissues. Research on zinc oxide nanoparticles (ZnONPs) has increasingly focused on their medicinal properties, especially regarding gene expression. Studies indicate that ZnONPs can enhance the expression of critical genes, such as glutathione peroxidase and superoxide dismutase, which are crucial for protecting cells from oxidative damage. Additionally, they have been shown to upregulate interleukin-8 (IL-8), a cytokine involved in the inflammatory response. This evidence suggests that ZnONPs have potential therapeutic applications in modulating oxidative stress and inflammation (Poon *et al.* 2020; Abdel-Latif *et al.* 2021).

Pourmohammad *et al.* (2021) have studied the influence of ZnO nanoparticles on

hepatic hepcidin gene expression to explore a potential treatment for iron overload and anemia. ZnO and ZnO nanoparticles were administered via injection to rats. Subsequent analyses measured serum concentrations of iron, ferritin, and interleukin-6 (IL-6). The expression levels of the hepcidin gene were assessed using real-time PCR, revealing significantly elevated expression in both the ZnO and ZnO nanoparticle groups compared to the control group. Associated with pure ZnO, ZnONPs significantly increased hepcidin gene expression. This demonstrated that hepcidin gene expression was dramatically upregulated after exposure to ZnO nanoparticles.

Jacob *et al.* (2023) found that the rate at which cells were taken up and kept by cells was strongly linked to several factors, including the nanoparticles' surface charge, size, and ligand properties. They concluded that LNPs with ligands are still used to target the liver and deliver medicines like siRNA, mRNA, and pDNA. Moreover, innovative functionalization strategies are currently being developed to enhance the stability of drugs, mitigate opsonization, facilitate the escape of endosomes, and enable the specific targeting of cells utilizing lipid nanoparticles (Park *et al.*, 2022).

The Limitations of Conventional Disease Treatment:

Conventional treatments typically aim to address the root causes of liver disease or damage while also working to reduce inflammation in the liver. These approaches may involve a combination of lifestyle changes, medications, and other therapies designed to restore liver health and prevent further complications (Tan *et al.*, 2021). Among various kinds of research, the activation of HSCs has emerged as a pivotal phenomenon that plays a crucial role in the process of fibrogenesis. This activation marks a significant turning point, initiating a cascade of events that ultimately contribute to the development of fibrosis within the liver (Bruno *et al.*, 2020; Wang *et al.*, 2023).

Therapies that rely exclusively on antifibrotic effects are insufficient to address the underlying factors contributing to disease processes, including cellular stress, inflammation, and apoptosis. Much of the research concentrates on the activation processes of hepatic stellate cells (HSCs) and inflammatory pathways; however, more attention should be given to the interactions between diverse cell types and organs. It is essential to address the etiology of liver disease and its associated complications (Gu *et al.*, 2022).

Mao *et al.* (2024), focus on established methodologies utilizing rodent models that mimic both the pathogenesis and severity of liver injuries observed in clinical environments, aiming to elucidate mechanisms underlying hepatotoxicity and to devise more effective therapeutic strategies. The primary objective is to develop robust rodent models that facilitate research into hepatoprotective agents and interventions against liver injury. The review encompasses various standard models employed for chemically induced liver injury, immune-mediated liver damage, alcoholic liver disease, and drug-induced hepatotoxicity. It provides an in-depth analysis of modeling techniques, cascades of pathogenic mechanisms, and action pathways while systematically assessing the advantages and limitations of each model. The insights from this review are intended to inform the development of more targeted theoretical frameworks for clinical liver injury treatment approaches (Mao *et al.* 2024).

Although biological drugs are effective, they have significant drawbacks regarding their stability and half-life, resulting in the need for frequent administration or even the implantation of a pump in patients (Peng *et al.*, 2021). This can lead to lower compliance and a greater risk of infection. According to Spagnolo *et al.*, there is still much-unresolved research and a significant need to devise a way to target the pathophysiological mechanism that specifically causes extracellular matrix (ECM) accumulation and makes it disappear. Effectively translating information into clinical therapies that can halt, or reverse fibrosis progression presents a considerable challenge (Ramos-Tovar and Muriel, 2020).

D. Treatment of Liver Fibrosis using Nanoparticles

a) Advantages of Using Nanoparticles for Liver Fibrosis Treatment:

Natural killer cells and macrophages are immune cells linked to liver fibrosis. Molecular processes like the failure of hepatocytes to regenerate, the release of inflammatory cytokines, and the buildup of too much extracellular matrix all play a part in developing liver fibrosis. Liver sinusoidal endothelial cells (LSECs) and hepatocytes also play essential roles in liver fibrosis (Bai *et al.*, 2020; Bhandari *et al.*, 2021). Nanoparticle drug delivery systems possess the capability to selectively target specific cell types, such as

hematopoietic stem cells (HSCs) and liver sinusoidal endothelial cells (LSECs), and modulate their therapeutic efficacy (Gil *et al.*, 2023).

Recent studies have illuminated the potential of nanotechnology-based interventions in treating liver fibrosis, offering hope for precision medicine approaches. Nanomedicine amplifies imaging contrast, promotes tissue penetration, and improves cellular internalization. It also accomplishes focused medication administration and combination therapy and serves diagnostic and therapeutic purposes, known as the nanostics (Mazari *et al.*, 2021; Sun *et al.*, 2021; Park *et al.*, 2022). Within the exciting field of nanomedicine, the concept of "nanostics" represents a pioneering approach that integrates imaging agents and therapeutic molecules within a singular nanoparticle. This avant-garde technique augments diagnostic accuracy and enhances the efficacy of treatments, thereby facilitating the development of more intelligent and targeted therapeutic strategies. Envision the potential of employing a diminutive carrier capable of visualization and treatment, thus transforming our approach to medicine (Ferreira *et al.*, 2020).

Since activated hepatic stellate cells (aHSC) are acknowledged as the principal contributors to liver fibrosis, contemporary nanoparticle (NP) therapies are directed at explicitly targeting HSC through various nanoparticulate systems. In the context of liver injury, macrophages are known to release profibrogenic factors that lead to the activation of HSC. Therefore, focusing on macrophages is a promising therapeutic approach for treating liver fibrosis, particularly given hepatocytes' significant role in promoting fibroblast accumulation within damaged hepatic tissue (Trivella *et al.*, 2020). Hue *et al.* conducted a study that shows synergistic antifibrotic effects in rodent models. A synergistic strategy that targets both macrophages and hepatocytes could enhance treatment efficacy. Several pharmacological agents are designed to address the various pathways associated with the progression of liver fibrosis related to macrophages and hepatocytes; however, only a limited number are currently being investigated in nanoparticle formulations (Hu, Lee, and Luo 2019). For liver fibrosis, different nanotechnology-based drug delivery methods have been studied. These include liposomes, protein-based delivery systems, and inorganic delivery systems. New research suggests that a helpful way to treat liver fibrosis could be to use delivery methods changed with hyaluronic acid (HA) and target liver sinusoidal endothelial cells (LSEC). Improved liver function has resulted from these approaches, which have decreased inflammation, accelerated scar tissue breakdown, and markedly reduced fibrosis markers—all of which play critical roles in developing hepatic fibrosis. Targeting LSEC specifically through these delivery methods can minimize off-target effects and improve treatment safety and efficacy. Overall, HA-modified delivery methods and LSEC targeting represent a promising new avenue for treating liver fibrosis (Bhandari *et al.*, 2021; Peng *et al.*, 2021; Essa *et al.*, 2022).

Lee *et al.* (2022) investigated the possibility that a specific anti-fibrotic impact could be achieved in the liver by Fibroblast Activation Protein (FAP) selectively liberating the anti-fibrotic peptide, melittin on the surfaces of aHSC overexpressing FAP. So, scientists devised a delivery mechanism that releases melittin into the fibrotic hepatic microenvironment by cleaving promelittin exclusively in FAP-expressing areas of the liver. Promelittin-modified liposomes (PRL) treatment shows that (PRL) has anti-fibrotic and survival-prolonging effects. They confirmed that (PRL) can be cleaved by FAP in fibrotic liver tissues, then FAP-liberated melittin kills aHSC and relieves fibrosis in mouse models.

Xia *et al.* (2023) have developed biomimetic nanoparticles that can effectively target and induce apoptosis in activated hepatic stellate cells (aHSCs), which are involved in liver fibrosis. These nanoparticles are coated with membranes expressing the tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and contain all-trans retinoic acid (ATRA) in the core. The biomimetic TRAIL coating targets HSCs and induces apoptosis in aHSCs, while ATRA can induce quiescence in activated fibroblasts. The combination of TRAIL-coated ATRA nanoparticles enhanced fibrosis improvement in mouse models of liver fibrosis. This novel approach may offer an effective antifibrosis therapy.

Other approaches have attempted to suppress HSC activation through metabolic regulation to promote anti-fibrotic effects (Khomich *et al.*, 2019; Mehal 2023). For instance, an adiponectin-based agonist inhibited HSC activation by regulating glucose and lipid metabolism via binding to appropriate receptors (Xu *et al.*, 2020). Likewise, Lipid

nanoparticles engineered with HSC surface-targeting ligands represent a promising advancement in hepatic fibrosis treatment. Their advantages over inorganic nanoparticles include reduced toxicity, enhanced biodegradability, and lower immunogenicity (Swarupananda, Ayon, and Dipanjana, 2021).

However, there are still challenges to overcome before clinical implementation. According to Tan *et al.* (2021) and Xing *et al.* (2021), activating hepatic stellate cells (HSCs) is an essential aspect of liver fibrosis and a significant target for therapies that attempt to reduce fibrosis. Numerous research studies have delved into the promising potential of therapies centered on hematopoietic stem cells (HSCs). These therapies are emerging as an exciting alternative treatment option for a wide range of medical conditions, showcasing the ability of HSCs to regenerate and repair damaged tissues and to modulate immune responses. Exploring HSC-based treatments holds the key to innovative approaches in medicine, offering hope for those affected by various diseases. (Fan *et al.*, 2020; Ruman *et al.*, 2020; Lee *et al.*, 2023; Zhao *et al.*, 2023)

Researchers have extensively studied targeting vectors and modified ligands to enhance the effectiveness of targeted therapy for liver fibrosis. Many nanocarriers and strategies have been created for liver fibrosis, providing a fresh way to target cell therapy and a theoretical basis for achieving the highly effective therapy goal (Bayda *et al.*, 2020).

According to Wei Peng and colleagues (2021), significant research has been done on the advancement of nanocarriers and targeted therapy techniques for liver fibrosis to enhance the effectiveness of treatment. Their research has concentrated on nano-delivery vectors and modified ligands, presenting a novel approach for precise cell treatment targeting. Liver fibrosis is a substantial health hazard.

Nanoparticles have emerged as effective carriers for anti-fibrotic agents. The field of nanotechnology holds promise for developing drug-delivery systems to combat liver fibrosis. However, advances in nanotechnology have led to the development of nanoprobe that have the potential to work as both drug-delivery agents and diagnostic tools (Eftekhari *et al.*, 2021; Rahman, 2023). Advanced nanotechnology strategies take advantage of the distinct characteristics of nanoscale materials, allowing for the development of novel solutions that address the challenges posed by current therapeutic methods. By harnessing these innovative techniques, researchers can create treatments that enhance the efficacy of interventions for liver fibrosis, potentially revolutionizing patient care and outcomes in this complex condition (Pop *et al.*, 2020; Gu *et al.*, 2022).

Bai *et al.* (2020) conducted a study that thoroughly examined potential targets and the application of novel nanomedicine systems for identifying and managing liver fibrosis. The systems include liposomes, polymers, proteins, inorganics, and hybrid nanoparticles. Compared to conventional methods, nanomedicine systems generally improve the treatment of liver fibrosis. The authors also examined the perspectives and challenges of successfully transitioning these nanomedicine systems from the confines of the laboratory to practical clinical applications (Zhai *et al.*, 2020). Pote *et al.* (2022) demonstrated the utility of mesoporous silica nanoparticles loaded with curcumin, a natural anti-fibrotic compound. The objective of the study was to make and describe silica adorned with curcumin-loaded zinc oxide nanoparticles to develop a tissue adhesive in the form of liquid stitches. The mesoporous silica nanoparticles serve to facilitate tissue adhesion through the mechanism of nano-bridging. The progression of fibrosis in rats was slowed down, and the sustained release and improved bioavailability of these nanoparticles suggested a possible way to deliver drugs to fibrotic areas. The extended duration and reduced adverse effects of drug administration via nanoparticles are attributed to their controlled-release features.

Zinc is highly appropriate as a prominent micronutrient and a necessary component for over 300 enzymes in the human body. Moreover, zinc plays a crucial role in various fundamental cellular functions, including regulating cellular redox equilibrium, DNA replication, DNA repair, cell cycle advancement, and programmed cell death (Kim *et al.*, 2020; Negrescu *et al.*, 2022). The work conducted by Ghosh *et al.* (2022) investigated different methods of synthesizing ZnO nanoparticles to explore their potential as carriers in nanomedicine for disease treatment. Elevated zinc levels have been demonstrated to induce protein imbalance, increasing oxidative stress within targeted cells.

Nevertheless, a decrease in zinc levels has been observed to expedite the advancement of Liver fibrosis. Zinc oxide (ZnO) nanoparticles have demonstrated

encouraging results in liver disease treatment owing to their aptitude for surface chemistry modification and enhanced permeability and retention effect (EPR). The potential of these nanoparticles in oncology warrants further investigation and could lead to the development of improved liver disease therapies (Perera *et al.*, 2020; He *et al.*, 2021).

b) Diagnostic Nanoprobe:

A liver biopsy is the standard diagnostic method for liver fibrosis. Liver fibrosis can be identified by staining the cells or extracellular matrix proteins using histological or histochemical techniques. Histological staining techniques frequently employed to assess liver fibrosis include hematoxylin-eosin with Masson's trichrome or Sirius Red staining (Heyens *et al.*, 2021).

It is possible to give "personalized treatment" to patients who show significant drug absorption by affected liver cells with the help of these versatile nanoparticles. Zhang & Zhang (2022) laid the foundation for creating a structured External Quality Assessment (EQA) to identify liver fibrosis biomarkers accurately. EQA is a crucial instrument for detecting issues in a clinical laboratory. The study emphasizes the constraints of accurately measuring liver fibrosis biomarkers using quantitative methods and proposes enhanced detection kits and quality control protocols. Additionally, it lays the groundwork for creating a structured External Quality Assessment (EQA) to identify biomarkers for liver fibrosis. Furthermore, it guides the choice of the appropriate apparatus, procedures, and reagents for laboratory detection of liver fibrosis indicators.

The most extensively researched biomarkers associated with liver fibrosis encompass the products resulting from extracellular matrix synthesis and degradation alongside the enzymes responsible for their generation or modification. These biomarkers include hyaluronic acid, matrix metalloproteinases, tissue inhibitors of metalloproteinases (TIMPs), and cytokines such as transforming growth factor beta (TGF- β). An essential characteristic of a prognostic marker lies in its capacity to anticipate the future onset of a disease (Mercedes *et al.*, 2020; Zhang & Zhang, 2022).

According to Loomba and Adams (2020), non-invasive techniques are needed to diagnose and determine the stage of liver fibrosis. They proposed using isotope techniques to measure the pace at which hepatic collagen is replaced in liver biopsies. *Plasma lumican* is a peptide that encourages collagen synthesis and is found in higher amounts in liver fibrosis. It dramatically affects this measurement because it shows how constant liver collagen is being replaced.

Sargazi *et al.* (2023) created nanosensors for diagnosing non-alcoholic fatty liver disease by modifying inorganic nanoparticles with polymers, bimetallic nanoparticles, superparamagnetic nanoparticles, and ultra-small superparamagnetic nanoparticles (Flores-Rojas *et al.*, 2022). Modifying several nanostructures with specific ligands or chemicals influencing liver tissues can enhance their effectiveness.

Conclusion

The versatility of nanotechnology can enhance its benefits, positioning it as a valuable asset across diverse medical fields and improving outcomes for a broader range of patients. This cutting-edge technology has the potential to be tailored and utilized in various medical contexts, thereby creating new opportunities for advancing patient care. Nanotechnology has advanced significantly in using nanoparticles to optimize the efficacy of combination therapy for different pathologies, particularly liver fibrosis. This discipline shows considerable promise for targeted drug delivery systems, facilitating prolonged release profiles and enhancing drug stability.

Recent advancements in nanoparticle-based drug delivery systems have demonstrated significant potential for transforming the management of liver fibrosis through targeted therapies and improved diagnostic methods. Studies consistently highlight the effectiveness of nanomaterials in ensuring precise drug delivery to hepatic tissues, which reduces the reliance on systemic administration and alleviates associated adverse effects. A key advantage of this approach is the direct delivery of drugs to the liver, which markedly increases their therapeutic potency.

Moreover, advancements in nanotechnology enable precise targeting of specific cells and tissues within the liver, allowing for personalized and more effective treatment strategies for liver fibrosis. This improved targeting enhances treatment outcomes and strengthens diagnostic capabilities, enabling earlier disease detection. Furthermore, these

innovations provide avenues for a deeper understanding of the underlying pathophysiological mechanisms associated with various conditions. Ultimately, these developments expand the repertoire of therapeutic options available, thereby increasing choices for patients and clinicians in managing liver fibrosis.

Recommendation:

Nanotechnology offers significant advantages in managing liver fibrosis, impacting millions globally. It enables the development of accurate diagnostic tools for early identification of the condition, allowing timely intervention. In therapy, it facilitates targeted drug delivery systems aimed at specific fibrotic tissue, reducing side effects and improving treatment efficacy. This precision could lead to personalized treatment plans and better patient outcomes. As research advances, we may see breakthroughs that enhance our understanding and revolutionize care for liver fibrosis.

Availability of Data and Materials:

It is important to note that data sharing does not apply to this review article, as no datasets were generated or analyzed. All the data referenced come from existing literature sources, which are comprehensively documented within the text.

Declarations:

Ethical Approval: Not applicable.

Competing interests: The authors declare that there is no conflict of interest.

Data Availability Statement: It is important to note that data sharing does not apply to this review article, as no datasets were generated or analyzed. All the data referenced come from existing literature sources, which are comprehensively documented within the text.

Authors Contributions: All authors contributed equally, and have read and agreed to the published version of the manuscript.

Funding: This study didn't receive any funding support.

Acknowledgments: Not applicable.

REFERENCES

- Abdel-Latif, Hany M. R., Mahmoud A. O. Dawood, Samy F. Mahmoud, Mustafa Shukry, Ahmed E. Noreldin, Hanan A. Ghetas, Mohamed A. Khallaf, and Francesco Fazio. 2021. "Copper Oxide Nanoparticles Alter Serum Biochemical Indices, Induce Histopathological Alterations, and Modulate Transcription of Cytokines, HSP70, and Oxidative Stress Genes in *Oreochromis Niloticus*." *Oreochromis Niloticus. Animals* 11. doi: 10.3390/ani.
- Abdullah, Abdullah Saad, Ibrahim El Tantawy El Sayed, Abdel Moneim A. El-Torgoman, Noweir Ahmad Alghamdi, Sami Ullah, S. Wageh, and Maher A. Kamel. 2021. "Preparation and Characterization of Silymarin-Conjugated Gold Nanoparticles with Enhanced Anti-Fibrotic Therapeutic Effects against Hepatic Fibrosis in Rats: Role of microRNAs as Molecular Targets." *Biomedicines* 9(12). doi: 10.3390/biomedicines 9121767.
- Acharya, Pragyan, Komal Chouhan, Sabine Weiskirchen, and Ralf Weiskirchen. 2021. "Cellular Mechanisms of Liver Fibrosis." *Frontiers in Pharmacology*, 12, 671640
- Adebayo, Olayinka A., Oluyemi Akinloye, and Oluwatosin A. Adaramoye. 2020. "Cerium Oxide Nanoparticles Attenuate Oxidative Stress and Inflammation in the Liver of Diethylnitrosamine-Treated Mice." *Biological Trace Element Research* 193(1): 214–25. doi: 10.1007/s12011-019-01696-5.
- Afzal, S. A. A. D., Bhutta, G. A., Waqas, K. A. S. H. I. F., Rana, S. A. M. R. E. E. N., Malik, A. R. I. F., Zeeshan, S. Y. E. D., & Naqvi, H. A. I. D. E. R. (2020). Effect of Zinc Oxide Nanoparticles on Liver Cirrhosis Induced by Carbon Tetrachloride in Albino Rats. *Pakistan Journal of Medical & Health Sciences*, 14, 1034-1038.
- Agame-Lagunes, Beatriz, Peter Grube-Pagola, Rebeca García-Varela, Alfonso Alexander-Aguilera, and Hugo S. García. 2021. "Effect of Curcumin Nanoemulsions Stabilized with Mag and Dag-Mcfas in a Fructose-Induced Hepatic Steatosis Rat Model." *Pharmaceutics* 13(4). doi: 10.3390/pharmaceutics13040509.
- Agarwal, Happy, Amatullah Nakara, and Venkat Kumar Shanmugam. 2019. "Anti-Inflammatory Mechanism of Various Metal and Metal Oxide Nanoparticles Synthesized Using Plant Extracts: A Review." *Biomedicine and Pharmacotherapy* 109:2561–72.

- Agnihotri, Jaya, Mahima Salian, Janhavi Mishra, Anas Shaikh, and Shaikh Mohd Fareed. 2023. "Liver Targeting Novel Trends in Therapies, Corresponding Author." *International Journal of Nanotechnology & Nanomedicine*, 8(1), 119-126.
- Al-Doaiss, Amin, Qais Jarrar, and Said Moshawih. 2020. "Hepatic Histopathological and Ultrastructural Alterations Induced by 10 Nm Silver Nanoparticles." *IET Nanobiotechnology* 14(5):405–11. doi: 10.1049/iet-nbt.2020.0039.
- Alshammari, Ghedeir M., Mohamed Anwar Abdelhalim, Mohammed S. Al-Ayed, Laila Naif Al-Harbi, and Mohammed Abdo Yahya. 2023. "Concomitant Sub-Chronic Administration of Small-Size Gold Nanoparticles Aggravates Doxorubicin-Induced Liver Oxidative and Inflammatory Damage, Hyperlipidemia, and Hepatic Steatosis." *Molecules*, 28(2), 796. doi: 10.3390/molecules28020796.
- Anselmo, Aaron C., and Samir Mitragotri. 2019. "Nanoparticles in the Clinic: An Update." *Bioengineering & Translational Medicine*, 4(3), e10143. doi: 10.1002/btm2.10143.
- Antimisiaris, S. G., A. Marazioti, M. Kannavou, E. Natsaridis, F. Gkartziou, G. Kogkos, and S. Mourtas. 2021. "Overcoming Barriers by Local Drug Delivery with Liposomes." *Advanced Drug Delivery Reviews* 174:53–86. doi: 10.1016/J.ADDR.2021.01.019.
- Attia, Noha, Dina M. Rostom, and Mohamed Mashal. 2022. "The Use of Cerium Oxide Nanoparticles in Liver Disorders: A Double-Sided Coin?" *Basic and Clinical Pharmacology and Toxicology* 130(3):349–63.
- Bai, Xue, Gaoxing Su, and Shumei Zhai. 2020. "Recent Advances in Nanomedicine for the Diagnosis and Therapy of Liver Fibrosis." *Nanomaterials* 10(10):1–18.
- Balachandran, Yekkuni L., Wei Wang, Hongyi Yang, Haiyang Tong, Lulu Wang, Feng Liu, Hongsong Chen, Kai Zhong, Ye Liu, and Xingyu Jiang. 2022. "Heterogeneous Iron Oxide/Dysprosium Oxide Nanoparticles Target Liver for Precise Magnetic Resonance Imaging of Liver Fibrosis." *ACS Nano*, 16(4):5647–59. doi: 10.1021/acsnano.1c10618.
- Ballestri, Stefano, Alessandro Mantovani, Enrica Baldelli, Simonetta Lugari, Mauro Maurantonio, Fabio Nascimbeni, Alessandra Marrazzo, Dante Romagnoli, Giovanni Targher, and Amedeo Lonardo. 2021. "Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease." *Diagnostics*, 11(1), 98. doi: 10.3390/diagnostics11010098.
- Bashandy, Samir A. E., Mohamed F. Abdelhameed, Omar A. H. Ahmed-Farid, Fatma A. Morsy, Fatma A. A. Ibrahim, and Marawan Elbaset. 2022. "The Pivotal Role of Cerium Oxide Nanoparticles in Thioacetamide Induced Hepatorenal Injury in Rat." *Egyptian Journal of Chemistry*, 65(10):267–78. doi: 10.21608/EJCHEM.2022.115482.5242.
- Bashandy, Samir A. E., Abdulaziz Alaamer, Sherif A. Abdelmottaleb Moussa, and Enayat A. Omara. 2018. "Role of Zinc Oxide Nanoparticles in Alleviating Hepatic Fibrosis and Nephrotoxicity Induced by Thioacetamide in Rats." *Canadian Journal of Physiology and Pharmacology*, 96(4):337–44. doi: 10.1139/cjpp-2017-0247.
- Bayda, Samer, Muhammad Adeel, Tiziano Tuccinardi, Marco Cordani, and Flavio Rizzolio. 2020. "The History of Nanoscience and Nanotechnology: From Chemical-Physical Applications to Nanomedicine." *Molecules*, 25(1), 112. doi: 10.3390/MOLECULES25010112.
- Beyene, Anteneh Marelign, Mohammad Moniruzzaman, Adhimoolam Karthikeyan, and Taesun Min. 2021. "Curcumin Nanoformulations with Metal Oxide Nanomaterials for Biomedical Applications." *Nanomaterials*, 11(2):1–25.
- Bhandari, Sabin, Anett Kristin Larsen, Peter McCourt, Bård Smedsrød, and Karen Kristine Sørensen. 2021. "The Scavenger Function of Liver Sinusoidal Endothelial Cells in Health and Disease." *Frontiers in Physiology* 12, 757469.
- Bilensoy, Erem, and Cem Varan. 2023. "Is There a Niche for Zinc Oxide Nanoparticles in Future Drug Discovery?" *Expert Opinion on Drug Discovery*, 18(9):943–45.
- Boey, Adrian, and Han Kiat Ho. 2020. "All Roads Lead to the Liver: Metal Nanoparticles and Their Implications for Liver Health." *Small*, 16(21), 2000153.
- Boey, Adrian, Shu Qing Leong, Sayali Bhawe, and Han Kiat Ho. 2021. "Cerium Oxide

- Nanoparticles Alleviate Hepatic Fibrosis Phenotypes in Vitro.” *International Journal of Molecular Sciences*, 22(21), 11777. doi: 10.3390/ijms222111777.
- Bondarenko, Olesja, Monika Mortimer, Anne Kahru, Neus Feliu, Ibrahim Javed, Aleksandr Kakinen, Sijie Lin, Tian Xia, Yang Song, Thomas P. Davis, Iseult Lynch, Wolfgang J. Parak, David Tai Leong, Pu Chun Ke, Chunying Chen, and Yuliang Zhao. 2021. “Nanotoxicology and Nanomedicine: The Yin and Yang of Nano-Bio Interactions for the New Decade.” *Nano Today*, 39:101184. doi: 10.1016/J.NANTOD. 2021. 101184.
- Bose, Anamika, Debanwita Roy Burman, Bismayan Sikdar, and Prasun Patra. 2021. “Nanomicelles: Types, Properties and Applications in Drug Delivery.” *IET Nanobiotechnology*, 15(1):19–27.
- Bruno, Stefania, Giulia Chiabotto, and Giovanni Camussi. 2020. “Extracellular Vesicles: A Therapeutic Option for Liver Fibrosis.” *International Journal of Molecular Sciences*, 21(12):1–18.
- Carmona, Rita, Silvia Barrena, and Ramón Muñoz-Chápuli. 2019. “Retinoids in Stellate Cells: Development, Repair, and Regeneration.” *Journal of Developmental Biology*, 7(2), 10.
- Carvajal, Silvia, Meritxell Perramón, Gregori Casals, Denise Oró, Jordi Ribera, Manuel Morales-Ruiz, Eudald Casals, Pedro Casado, Pedro Melgar-Lesmes, Guillermo Fernández-Varo, Pedro Cutillas, Victor Puentes, and Wladimiro Jiménez. 2019. “Cerium Oxide Nanoparticles Protect against Oxidant Injury and Interfere with Oxidative Mediated Kinase Signaling in Human-Derived Hepatocytes.” *International Journal of Molecular Sciences*, 20(23), 5959. doi: 10.3390/ijms20235959.
- Casals, Gregori, Meritxell Perramón, Eudald Casals, Irene Portolés, Guillermo Fernández-Varo, Manuel Morales-Ruiz, Victor Puentes, and Wladimiro Jiménez. 2021. “Cerium Oxide Nanoparticles: A New Therapeutic Tool in Liver Diseases.” *Antioxidants*, 10(5), 660.
- Castro-Pastrana, Lucila Isabel, Aracely Angulo Molina, Jessica Andrea Flood-Garibay, Dulce Alitzel Quintana-Romero, Pablo Crespo-Morán, and Miguel Ángel Méndez-Rojas. 2021. “Recent Advances on Nanostructured Materials for Drug Delivery and Release.” Pp. 319–60 in.
- Chen, Zhijin, Akshay Jain, Hao Liu, Zhen Zhao, and Kun Cheng. 2019. “Targeted Drug Delivery to Hepatic Stellate Cells for the Treatment of Liver Fibrosis.” *Journal of Pharmacology and Experimental Therapeutics*, 370(3):695–702.
- Cheng, Da, Jin Chai, Huiwen Wang, Lei Fu, Shifang Peng, and Xin Ni. 2021. “Hepatic Macrophages: Key Players in the Development and Progression of Liver Fibrosis.” *Liver International*, 41(10):2279–94.
- Cheng, Xiaoxiao, Qirong Xie, and Yang Sun. 2023. “Advances in Nanomaterial-Based Targeted Drug Delivery Systems.” *Frontiers in Bioengineering and Biotechnology*, 11, 1177151.
- Chiu, Hock Ing, Nozlana Abdul Samad, Lizhen Fang, and Vuanghao Lim. 2021. “Cytotoxicity of Targeted PLGA Nanoparticles: A Systematic Review.” *RSC Advances*, 11(16):9433–49.
- Colino, Clara I., José M. Lanao, and Carmen Gutierrez-Millan. 2020. “Targeting of Hepatic Macrophages by Therapeutic Nanoparticles.” *Frontiers in Immunology*, 11, 218.
- Córdoba-Jover, Bernat, Altamira Arce-Cerezo, Jordi Ribera, Montse Pauta, Denise Oró, Gregori Casals, Guillermo Fernández-Varo, Eudald Casals, Victor Puentes, Wladimiro Jiménez, and Manuel Morales-Ruiz. 2019. “Cerium Oxide Nanoparticles Improve Liver Regeneration after Acetaminophen-Induced Liver Injury and Partial Hepatectomy in Rats.” *Journal of Nanobiotechnology*, 17(1). 1–12. doi: 10.1186/s12951-019-0544-5.
- Dadfar, Seyed Mohammadali, Karolin Roemhild, Natascha I. Drude, Saskia von Stillfried, Ruth Knüchel, Fabian Kiessling, and Twan Lammers. 2019. “Iron Oxide Nanoparticles: Diagnostic, Therapeutic and Theranostic Applications.” *Advanced Drug Delivery Reviews*, 138:302–25.
- Debacker, Alexandre J., Jon Voutila, Matthew Catley, David Blakey, and Nagy Habib. 2020. “Delivery of Oligonucleotides to the Liver with GalNAc: From Research to

- Registered Therapeutic Drug.” *Molecular Therapy*, 28(8):1759–71.
- Deka, Bhabesh, Chittaranjan Baruah, Azariah Babu, and Pankaj Kalita. 2022. *Biological and Non-Conventional Synthesis of Zinc Oxide Nanoparticles (ZnO-NPs): Their Potential Applications*. *Journal of Nanotechnology and Nanomaterials* 3.2: 79-89
- Delgado, M. Eugenia, Beatriz I. Cárdenas, Núria Farran, and Mercedes Fernandez. 2021. “Metabolic Reprogramming of Liver Fibrosis.” *Cells*, 10(12). 3604.
- Devaraj, Ezhilarasan, and S. Rajeshkumar. 2020. “Nanomedicine for Hepatic Fibrosis.” Pp. 45–64 in *Nanoparticles and their Biomedical Applications*. Springer Singapore.
- Dong, Xiaotian, Jingqi Liu, Yanping Xu, and Hongcui Cao. 2019. “Role of Macrophages in Experimental Liver Injury and Repair in Mice (Review).” *Experimental and Therapeutic Medicine*, 17(5), 3835–3847. Doi: 10.3892/etm.2019.7450.
- Du, Xiaoqing, Yuqi Hou, Jia Huang, Yan Pang, Chenlu Ruan, Wei Wu, Chenjie Xu, Hongwei Zhang, Lifang Yin, and Wei He. 2021. “Cytosolic Delivery of the Immunological Adjuvant Poly I: C and Cytotoxic Drug Crystals via a Carrier-Free Strategy Significantly Amplifies Immune Response.” *Acta Pharmaceutica Sinica B*, 11(10):3272–85. doi: 10.1016/j.apsb.2021.03.014.
- Durán-Lobato, Matilde, Ana María López-Estévez, Ana Sara Cordeiro, Tamara G. Dacoba, José Crecente-Campo, Dolores Torres, and María José Alonso. 2021. “Nanotechnologies for the Delivery of Biologicals: Historical Perspective and Current Landscape.” *Advanced Drug Delivery Reviews*, 176, 113899.
- Eftekhari, Aziz, Allahveirdy Arjmand, Ayyub Asheghvatan, Helena Švajdlénková, Ondrej Šauša, Huseyn Abiyev, Elham Ahmadian, Oleh Smutok, Rovshan Khalilov, Taras Kavetsky, and Magali Cucchiari. 2021. “The Potential Application of Magnetic Nanoparticles for Liver Fibrosis Theranostics.” *Frontiers in Chemistry*, 9, 674786.
- Elfaky, Mahmoud A., Alaa Sirwi, Sameh H. Ismail, Heba H. Awad, and Sameh S. Gad. 2022. “Hepatoprotective Effect of Silver Nanoparticles at Two Different Particle Sizes: Comparative Study with and without Silymarin.” *Current Issues in Molecular Biology*, 44(7):2923–38. doi: 10.3390/cimb44070202.
- El-Kattan, Noura, Ahmed N. Emam, Ahmed S. Mansour, Mostafa A. Ibrahim, Ashraf B. Abd El-Razik, Kamilia A. M. Allam, Nadia Youssef Riad, and Samir A. Ibrahim. 2022. “Curcumin Assisted Green Synthesis of Silver and Zinc Oxide Nanostructures and Their Antibacterial Activity against Some Clinical Pathogenic Multi-Drug-Resistant Bacteria.” *RSC Advances*, 12(28):18022–38. doi: 10.1039/d2ra00231k.
- Elzoheiry, Alya, Esraa Ayad, Nahed Omar, Kadry Elbakry, and Ayman Hyder. 2022. “Anti-Liver Fibrosis Activity of Curcumin/Chitosan-Coated Green Silver Nanoparticles.” *Scientific Reports*, 12(1), 18403. doi: 10.1038/s41598-022-23276-9.
- Essa, Marwa Labib, Aya A. Elashkar, Nemany A. N. Hanafy, Eman M. Saied, and Maged El-Kemary. 2022. “Dual Targeting Nanoparticles Based on Hyaluronic and Folic Acids as a Promising Delivery System of the Encapsulated 4-Methylumbelliferone (4-MU) against Invasiveness of Lung Cancer in Vivo and in Vitro.” *International Journal of Biological Macromolecules*, 206:467–80. doi: 10.1016/J. IJBIOMAC. 2022.02.095.
- Fan, Qian Qian, Cheng Lu Zhang, Jian Bin Qiao, Peng Fei Cui, Lei Xing, Yu Kyoung Oh, and Hu Lin Jiang. 2020. “Extracellular Matrix-Penetrating Nanodrill Micelles for Liver Fibrosis Therapy.” *Biomaterials*, 230:119616. Doi: 10.1016/J. BIOMATERIALS.2019.119616.
- Fernández-Barahona, Irene, María Muñoz-Hernando, Jesus Ruiz-Cabello, Fernando Herranz, and Juan Pellico. 2020. “Iron Oxide Nanoparticles: An Alternative for Positive Contrast in Magnetic Resonance Imaging.” *Inorganics*, 8(4), 28. doi: 10.3390/inorganics8040028.
- Ferreira, Maria, João Sousa, Alberto Pais, and Carla Vitorino. 2020. “The Role of Magnetic Nanoparticles in Cancer Nanotheranostics.” *Materials*, 13(2), 266.
- Filip, Mara, Ioana Baldea, Luminita David, Bianca Moldovan, Gabriel Cristian Flontas, Sergiu Macavei, Dana Maria Muntean, Nicoleta Decea, Adrian Bogdan Tigau, and Simona Valeria Clichici. 2023. “Hybrid Material Based on Vaccinium Myrtillus L. Extract and Gold Nanoparticles Reduces Oxidative Stress and Inflammation in

- Hepatic Stellate Cells Exposed to TGF- β .” *Biomolecules*, 13(8), 1271. doi: 10.3390/biom13081271.
- Flores-Rojas, Guadalupe Gabriel, Felipe López-Saucedo, Ricardo Vera-Graziano, Eduardo Mendizabal, and Emilio Bucio. 2022. “Magnetic Nanoparticles for Medical Applications: Updated Review.” *Macromol*, 2(3):374–390. doi: 10.3390/macromol2030024.
- Georgilis, Evangelos, Mona Abdelghani, Jan Pille, Esra Aydinlioglu, Jan C. M. Van Hest, Sébastien Lecommandoux, and Elisabeth Garanger. 2020. “Nanoparticles Based on Natural, Engineered or Synthetic Proteins and Polypeptides for Drug Delivery Applications.” *International Journal of Pharmaceutics*, 586:119537. doi: 10.1016/j.ijpharm.2020.119537.
- Ghosh, Noyel, Sharmistha Chatterjee, Mousumi Kundu, and Parames C. Sil. 2022. “Oxidative Stress-Dependent Anticancer Potentiality of Nanotherapeutic Zinc Oxide.” Pp. 2829–50 in *Handbook of Oxidative Stress in Cancer: Therapeutic Aspects: Volume 1*. Vol. 1. Springer Singapore.
- Gil, Mar, Lareen Khouri, Imma Raurell, Diana Rafael, Fernanda Andrade, Ibane Abasolo, Simo Schwartz, María Martínez-Gómez, María Teresa Salcedo, Juan Manuel Pericàs, Diana Hide, Mingxing Wei, Norman Metanis, Joan Genescà, and Maria Martell. 2023. “Optimization of Statin-Loaded Delivery Nanoparticles for Treating Chronic Liver Diseases by Targeting Liver Sinusoidal Endothelial Cells.” *Pharmaceutics*, 15(10):2463–2460. doi: 10.3390/pharmaceutics15102463.
- Gracia-Sancho, Jordi, Esther Caparrós, Anabel Fernández-Iglesias, and Rubén Francés. 2021. “Role of Liver Sinusoidal Endothelial Cells in Liver Diseases.” *Nature Reviews Gastroenterology and Hepatology*, 18(6):411–31.
- Gu, Lihong, Feng Zhang, Jinhui Wu, and Yuzheng Zhuge. 2022. “Nanotechnology in Drug Delivery for Liver Fibrosis.” *Frontiers in Molecular Biosciences*, 8, 804396.
- Haddadzadegan, Soheil, Farid Dorkoosh, and Andreas Bernkop-Schnürch. 2022. “Oral Delivery of Therapeutic Peptides and Proteins: Technology Landscape of Lipid-Based Nanocarriers.” *Advanced Drug Delivery Reviews*, 182, 114097.
- Han, Zhipeng, Zhuang Li, Yi Li, Denghui Shang, Liangbo Xie, Yueqin Lv, Sihui Zhan, and Wenping Hu. 2022. “Enhanced Electron Transfer and Hydrogen Peroxide Activation Capacity with N, P-Codoped Carbon Encapsulated CeO₂ in Heterogeneous Electro-Fenton Process.” *Chemosphere*, 287:132154. Doi: 10.1016/J.CHEMOSPHERE. 2021.132154.
- Hashim, Mariam, Huma Mujahid, Samina Hassan, Shanila Bukhari, Iram Anjum, Christophe Hano, Bilal Haider Abbasi, and Sumaira Anjum. 2022. “Implication of Nanoparticles to Combat Chronic Liver and Kidney Diseases: Progress and Perspectives.” *Biomolecules*, 12(10), 1337.
- He, Haisheng, Yi Lu, Jianping Qi, Quangang Zhu, Zhongjian Chen, and Wei Wu. 2019. “Adapting Liposomes for Oral Drug Delivery.” *Acta Pharmaceutica Sinica B*, 9(1):36–48.
- He, Yuanyuan, Raimundo Fernandes de Araújo Júnior, Luis J. Cruz, and Christina Eich. 2021. “Functionalized Nanoparticles Targeting Tumor-Associated Macrophages as Cancer Therapy.” *Pharmaceutics*, 13(10), 1670.
- Heyens, Leen J. M., Dana Busschots, Ger H. Koek, Geert Robaeys, and Sven Francque. 2021. “Liver Fibrosis in Non-Alcoholic Fatty Liver Disease: From Liver Biopsy to Non-Invasive Biomarkers in Diagnosis and Treatment.” *Frontiers in Medicine*, 8, 615978.
- Hintermann, Edith, and Urs Christen. 2019. “The Many Roles of Cell Adhesion Molecules in Hepatic Fibrosis.” *Cells*, 8(12), 1503.
- Hu, Chenxia, Lingfei Zhao, Jinfeng Duan, and Lanjuan Li. 2019. “Strategies to Improve the Efficiency of Mesenchymal Stem Cell Transplantation for Reversal of Liver Fibrosis.” *Journal of Cellular and Molecular Medicine*, 23(3):1657–70.
- Hu, Mengying, Ying Wang, Zhengsheng Liu, Zhuo Yu, Kaiyun Guan, Mengrui Liu, Menglin Wang, Jun Tan, and Leaf Huang. 2021. “Hepatic Macrophages Act as a Central Hub for Relaxin-Mediated Alleviation of Liver Fibrosis.” *Nature Nanotechnology*, 16(4):466–77. doi: 10.1038/s41565-020-00836-6.
- Hu, Qiaobin, Ji Young Lee, and Yangchao Luo. 2019. “Nanoparticles Targeting Hepatic

- Stellate Cells for the Treatment of Liver Fibrosis.” *Engineered Science*, 6:12–21.
- Huang, Hau-Lun, Chih-Ho Lai, Wan-Hua Tsai, Kuo-Wei Chen, Shin-Lei Peng, Jui-Hsiang Lin, and Yu-Hsin Lin. 2024. “Nanoparticle-Enhanced Postbiotics: Revolutionizing Cancer Therapy through Effective Delivery.” *Life Sciences*, 337:122379. doi: 10.1016/j.lfs.2023.122379.
- Huang, Ting, Tianyuan Zhang, Xinchu Jiang, Ai Li, Yuanqin Su, Qiong Bian, Honghui Wu, Ruyi Lin, Ni Li, Hongcui Cao, Daishun Ling, Jinqiang Wang, Yasuhiko Tabata, Zhen Gu, and Jianqing Gao. 2021. “Bioengineering Iron Oxide Nanoparticles Augment the Intercellular Mitochondrial Transfer-Mediated Therapy”. *Science advances*, 7(40), eabj0534.
- Ibrahimiya, Nur Aisah, Gwenny Ichsan Prabowo, Lina Lukitasari, and Raditya Weka Nugraheni. 2023. “Nanoemulsion of Turmeric in VCO Inhibit the Progressivity of Lung Fibrosis Due to Cigarette Exposure.” *Sains Malaysiana*, 52(3):877–85. doi: 10.17576/jsm-2023-5203-15.
- Ijaz, Irfan, Ezaz Gilani, Ammara Nazir, and Aysha Bukhari. 2020. “Detail Review on Chemical, Physical and Green Synthesis, Classification, Characterizations and Applications of Nanoparticles.” *Green Chemistry Letters and Reviews*, 13(3):59–81.
- Jacob, S, A. B. Nair, S. H. S. Boddu, R. K. Abuhijleh, K. Selvaraju, T. Babu, B. Gorain, J. Shah, M. A. Morsy, and Shery Jacob. 2023. “The Emerging Role of Lipid Nanosystems and Nanomicelles in Liver Diseases”. *European Review for Medical & Pharmacological Sciences*, 27(18).
- Jampilek, Josef, and Katarina Kralova. 2020. “Potential of Nanonutraceuticals in Increasing Immunity.” *Nanomaterials*, 10(11):1–47.
- Jin, Su Eon, and Hyo Eon Jin. 2019. “Synthesis, Characterization, and Three-Dimensional Structure Generation of Zinc Oxide-Based Nanomedicine for Biomedical Applications.” *Pharmaceutics*, 11(11), 575.
- Kamm, Dakota R, Kyle S Mccommis, Ian Forsythe, Maria Chondronikola, D R Kamm, and K S Mccommis. 2022. “Hepatic Stellate Cells in Physiology and Pathology.” *The Journal of Physiology*, 600:1825–37. doi: 10.1113/JP281061#support-information-section.
- Kanamori, Yohei, Miyako Tanaka, Michiko Itoh, Kozue Ochi, Ayaka Ito, Isao Hidaka, Isao Sakaida, Yoshihiro Ogawa, and Takayoshi Suganami. 2021. “Iron-Rich Kupffer Cells Exhibit Phenotypic Changes during the Development of Liver Fibrosis in NASH.” *IScience*, 24(2), 102032. doi: 10.1016/j.isci.2020.102032.
- Kaps, Leonard, María José Limeres, Paul Schneider, Malin Svensson, Yanira Zeyn, Silvia Fraude, Maximiliano L. Cacicedo, Peter R. Galle, Stephan Gehring, and Matthias Bros. 2023. “Liver Cell Type-Specific Targeting by Nanoformulations for Therapeutic Applications.” *International Journal of Molecular Sciences*, 24(14), 11869.
- Karsdal, Morten A., Samuel J. Daniels, Signe Holm Nielsen, Cecilie Bager, Daniel G. K. Rasmussen, Rohit Loomba, Rambabu Surabattula, Ida Falk Villesen, Yi Luo, Diane Shevell, Natasja S. Gudmann, Mette J. Nielsen, Jacob George, Rose Christian, Diana J. Leeming, and Detlef Schuppan. 2020. “Collagen Biology and Non-Invasive Biomarkers of Liver Fibrosis.” *Liver International*, 40(4):736–50.
- Keerthana, S., and A. Kumar. 2020. “Potential Risks and Benefits of Zinc Oxide Nanoparticles: A Systematic Review.” *Critical Reviews in Toxicology*, 50(1):47–71.
- Keservani, Raj K., Sharma Anil K., and Kesharwani Rajesh K. 2018. *Drug Delivery Approaches and Nanosystems Volume 2: Drug Targeting Aspects of Nanotechnology*, CRC Press.
- Khan, Ibrahim, Khalid Saeed, and Idrees Khan. 2019. “Nanoparticles: Properties, Applications and Toxicities.” *Arabian Journal of Chemistry*, 12(7):908–31. doi: 10.1016/J.ARABJC.2017.05.011.
- Khomich, Olga, Alexander Ivanov, Birke Bartosch, and Alexander V Ivanov. 2019. “Metabolic Hallmarks of Hepatic Stellate Cells in Liver Fibrosis.” *Cells*, 9(1), 24. doi: 10.3390/cells9010024.
- Kim, Sung Won, Gwang Bum Im, Yu Jin Kim, Yeong Hwan Kim, Tae Jin Lee, and Suk Ho

- Bhang. 2020. "Bio-Application of Inorganic Nanomaterials in Tissue Engineering." Pp. 115–30 in *Advances in Experimental Medicine and Biology*, Vol. 1249. Springer.
- Kimura, Seigo, and Hideyoshi Harashima. 2023. "On the Mechanism of Tissue-Selective Gene Delivery by Lipid Nanoparticles." *Journal of Controlled Release*, 362:797–811. doi: 10.1016/J.JCONREL.2023.03.052.
- Kittel, Yonca, Alexander J. C. Kuehne, and Laura De Laporte. 2022. "Translating Therapeutic Microgels into Clinical Applications." *Advanced Healthcare Materials*, 11(6), 2101989.
- Krauss, Aviva C., Xin Gao, Liang Li, Michael L. Manning, Paresma Patel, Wentao Fu, Kumar G. Janoria, Gerlie Gieser, David A. Bateman, Donna Przepiorka, Yuan Li Shen, Stacy S. Shord, Christopher M. Sheth, Anamitro Banerjee, Jiang Liu, Kirsten B. Goldberg, Ann T. Farrell, Gideon M. Blumenthal, and Richard Pazdur. 2019. "FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia." *Clinical Cancer Research*, 25(9):2685–90. doi: 10.1158/1078-0432.CCR-18-2990.
- Kumar, Rahul, Daphika S. Dkhar, Rohini Kumari, Divya, Supratim Mahapatra, Vikash Kumar Dubey, and Pranjal Chandra. 2022. "Lipid Based Nanocarriers: Production Techniques, Concepts, and Commercialization Aspect." *Journal of Drug Delivery Science and Technology*, 74:103526. Doi: 10.1016/J.JDDST.2022.103526.
- Kumar, Raj. 2018. "Lipid-Based Nanoparticles for Drug-Delivery Systems." Pp. 249–84 in *Nanocarriers for Drug Delivery: Nanoscience and Nanotechnology in Drug Delivery*. Elsevier Science Ltd.
- Kumar, Virender, Xiaofei Xin, Jingyi Ma, Chalet Tan, Natalia Osna, and Ram I. Mahato. 2021. "Therapeutic Targets, Novel Drugs, and Delivery Systems for Diabetes Associated NAFLD and Liver Fibrosis." *Advanced Drug Delivery Reviews*, 176:113888. Doi:10. 1016/DJ.ADDR.2021.113888.
- Kurniawan, Dhadhang Wahyu, Richell Booijink, Lena Pater, Irene Wols, Aggelos Vrynas, Gert Storm, Jai Prakash, and Ruchi Bansal. 2020. "Fibroblast Growth Factor 2 Conjugated Superparamagnetic Iron Oxide Nanoparticles (FGF2-SPIONs) Ameliorate Hepatic Stellate Cells Activation in Vitro and Acute Liver Injury in Vivo." *Journal of Controlled Release*, 328:640–52. doi: 10.1016/j.jconrel.2020.09.041.
- Kusumoputro, Sydney, Christian Au, Katie H. Lam, Nathaniel Park, Austin Hyun, Emily Kusumoputro, Xiang Wang, and Tian Xia. 2023. "Liver-Targeting Nanoplatforms for the Induction of Immune Tolerance." *Nanomaterials*, 14(1):67. doi: 10.3390/nano14010067.
- Lebda, Fatma M., Sahar M. El Agaty, Radwa H. Ali, Ghada Galal Hamam, Aliaa M. Abd El-Monem, and Noha N. Lasheen. 2022. "Cerium Oxide Nanoparticles Modulate Liver X Receptor and Short Heterodimer Partner, and Attenuate Liver Steatosis and Steatohepatitis in a Rat Model of Postmenopausal Obesity." *General Physiology and Biophysics*, 41(5):431–46. doi: 10.4149/gpb_202235.
- Lee, Jaiwoo, Junho Byun, Gayong Shim, and Yu Kyoung Oh. 2022. "Fibroblast Activation Protein Activated Antifibrotic Peptide Delivery Attenuates Fibrosis in Mouse Models of Liver Fibrosis." *Nature Communications*, 13(1), 1516. doi: 10.1038/s41467-022-29186-8.
- Li, Jiulong, Chunying Chen, and Tian Xia. 2022. "Understanding Nanomaterial–Liver Interactions to Facilitate the Development of Safer Nanoapplications." *Advanced Materials*, 34(11), 2106456.
- Li, Xiaotong, Xiuju Peng, Makhlofi Zoulikha, George Frimpong Boafo, Kosheli Thapa Magar, Yanmin Ju, and Wei He. 2024. "Multifunctional Nanoparticle-Mediated Combining Therapy for Human Diseases." *Signal Transduction and Targeted Therapy*, 9(1), 1.
- Lin, Qixiong, Yueyou Peng, Yanyan Wen, Xiaoqiong Li, Donglian Du, Weibin Dai, Wei Tian, and Yanfeng Meng. 2023. "Recent Progress in Cancer Cell Membrane-Based Nanoparticles for Biomedical Applications." *Beilstein Journal of Nanotechnology*, 14:262–79.
- Liu, Qi, Xiang Wang, Xiangsheng Liu, Sanjan Kumar, Grant Gochman, Ying Ji, Yu Pei

- Liao, Chong Hyun Chang, Wesley Situ, Jianqin Lu, Jinhong Jiang, Kuo Ching Mei, Huan Meng, Tian Xia, and Andre E. Nel. 2019. "Use of Polymeric Nanoparticle Platform Targeting the Liver to Induce Treg-Mediated Antigen-Specific Immune Tolerance in a Pulmonary Allergen Sensitization Model." *ACS Nano*, 13(4):4778–94. doi: 10.1021/acsnano.9b01444.
- Loomba, Rohit, and Leon A. Adams. 2020. "Advances in Non-Invasive Assessment of Hepatic Fibrosis." *Gut*, 69(7):1343–52.
- Lopez-Muñoz, Gerardo A., Maria Alejandra Ortega, Ainhoa Ferret-Miñana, Francesco De Chiara, and Javier Ramón-Azcón. 2020. "Direct and Label-Free Monitoring of Albumin in 2d Fatty Liver Disease Model Using Plasmonic Nanogratings." *Nanomaterials*, 10(12):1–11. doi: 10.3390/nano10122520.
- López-Saucedo, Felipe, Guadalupe G. Flores-Rojas, H. Iván Meléndez-Ortiz, Adriana Morfín-Gutierrez, Marco A. Luna-Straffon, and Emilio Bucio. 2018. "Stimuli-Responsive Nanomaterials for Drug Delivery." Pp. 375–424 in *Characterization and Biology of Nanomaterials for Drug Delivery: Nanoscience and Nanotechnology in Drug Delivery*. Elsevier.
- Lu, Hongyun, Shengliang Zhang, Jinling Wang, and Qihe Chen. 2021. "A Review on Polymer and Lipid-Based Nanocarriers and Its Application to Nano-Pharmaceutical and Food-Based Systems." *Frontiers in Nutrition*, 8, 783831.
- Ma, Jane, Bridget Bishoff, R. R. Mercer, Mark Barger, Diane Schwegler-Berry, and Vincent Castranova. 2017. "Role of Epithelial-Mesenchymal Transition (EMT) and Fibroblast Function in Cerium Oxide Nanoparticles-Induced Lung Fibrosis." *Toxicology and Applied Pharmacology*, 323:16–25. doi: 10.1016/j.taap. 2017. 03.015.
- Mandal, Ashok Kumar, Saurav Katuwal, Felix Tettey, Aakash Gupta, Salyan Bhattarai, Shankar Jaisi, Devi Prasad Bhandari, Ajay Kumar Shah, Narayan Bhattarai, and Niranjana Parajuli. 2022. "Current Research on Zinc Oxide Nanoparticles: Synthesis, Characterization, and Biomedical Applications." *Nanomaterials*, 8, 783831.
- Mao, Jingxin, Lihong Tan, Cheng Tian, Wenxiang Wang, Hao Zhang, Zhaojing Zhu, and Yan Li. 2024. "Research Progress on Rodent Models and Its Mechanisms of Liver Injury." *Life Sciences*, 337:122343. doi: 10.1016/j.lfs.2023.122343.
- Martínez-Sánchez, Celia, Octavi Bassegoda, Hongping Deng, Xènia Almodóvar, Ainitze Ibarzabal, Ana de Hollanda, Raquel-Adela –A Martínez García de la Torre, Delia Blaya, Silvia Ariño, Natalia Jiménez-Esquivel, Beatriz Aguilar-Bravo, Julia Vallverdú, Carla Montironi, Oscar Osorio-Conles, Yiliam Fundora, Francisco Javier Sánchez Moreno, Alicia G. Gómez-Valadés, Laia Aguilar-Corominas, Anna Soria, Elisa Pose, Adrià Juanola, Marta Cervera, Martina Perez, Virginia Hernández-Gea, Silvia Affò, Kelly S. Swanson, Joana Ferrer-Fàbrega, Jose Maria Balibrea, Pau Sancho-Bru, Josep Vidal, Pere Ginès, Andrew M. Smith, Isabel Graupera, and Mar Coll. 2023. "Therapeutic Targeting of Adipose Tissue Macrophages Ameliorates Liver Fibrosis in Non-Alcoholic Fatty Liver Disease." *JHEP Reports*, 5(10), 100830. doi: 10.1016/j.jhepr.2023.100830.
- Mazari, Shaukat Ali, Esfandiyar Ali, Rashid Abro, Fahad Saleem Ahmed Khan, Israr Ahmed, Mushtaq Ahmed, Sabzoi Nizamuddin, Tahir Hussain Siddiqui, Nazia Hossain, Nabisab Mujawar Mubarak, and Asif Shah. 2021. "Nanomaterials: Applications, Waste-Handling, Environmental Toxicities, and Future Challenges - A Review." *Journal of Environmental Chemical Engineering*, 9(2), 05028. doi: 10. 1016/j.jece.2021.105028.
- Mehal, Wajahat. 2023. "Mechanisms of Liver Fibrosis in Metabolic Syndrome." *EGastroenterology* 1(1):e100015. doi: 10.1136/egastro-2023-100015.
- Mehta, Meenu, Thuy Anh Bui, Xinpu Yang, Yagiz Aksoy, Ewa M. Goldys, and Wei Deng. 2023. "Lipid-Based Nanoparticles for Drug/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development." *ACS Materials Au*, 3(6):600–619.
- Mercedes, Rebecca, Jameisha Brown, Charles Minard, Cynthia M. Tsai, Sridevi Devaraj, Marthe Munden, and Daniel Leung. 2020. "A Liver Biopsy Validation Pilot Study of Shear Wave Elastography, APRI, FIB-4, and Novel Serum Biomarkers for Liver

- Fibrosis Staging in Children with Chronic Viral Hepatitis.” *Global Pediatric Health*, 7, 2333794X20938931. doi: 10.1177/2333794X20938931.
- Mitchell, Michael J., Margaret M. Billingsley, Rebecca M. Haley, Marissa E. Wechsler, Nicholas A. Peppas, and Robert Langer. 2021. “Engineering Precision Nanoparticles for Drug Delivery.” *Nature Reviews Drug Discovery*, 20(2):101–24.
- Moatamed, Eman Raafat, Aida Ahmed Hussein, Mohamed Mahmoud El-desoky, and Zakaria E. L. Khayat. 2019. “Comparative Study of Zinc Oxide Nanoparticles and Its Bulk Form on Liver Function of Wistar Rat.” *Toxicology and Industrial Health*, 35(10):627–37. doi: 10.1177/0748233719878970.
- Mohammad Yousof, Shimaa, Horeya Erfan, Marwa Mohamed Hosny, Shaimaa A. Shehata, and Karima El-Sayed. 2022. “Subacute Toxic Effects of Silver Nanoparticles Oral Administration and Withdrawal on the Structure and Function of Adult Albino Rats’ Hepatic Tissue.” *Saudi Journal of Biological Sciences*, 29(5):3890–98. doi: 10.1016/j.sjbs.2022.02.054.
- Molenaar, Martijn R., Louis C. Penning, and J. Bernd Helms. 2020. “Playing Jekyll and Hyde the Dual Role of Lipids in Fatty Liver Disease.” *Cells*, 9(10):1–23.
- Murar, Madhura, Lorenzo Albertazzi, and Silvia Pujals. 2022. “Advanced Optical Imaging-Guided Nanotheranostics toward Personalized Cancer Drug Delivery.” *Nanomaterials*, 12(3), 399.
- Nag, Okhil K., and James B. Delehanty. 2023. “Special Issue ‘Nanoparticle-Mediated Drug Delivery, Imaging, and Control of Cellular Functions.’” *Pharmaceuticals*, 16(10), 1344.
- Namiot, Eugenia D., Aleksandr V. Sokolov, Vladimir N. Chubarev, Vadim V. Tarasov, and Helgi B. Schiöth. 2023. “Nanoparticles in Clinical Trials: Analysis of Clinical Trials, FDA Approvals and Use for COVID-19 Vaccines.” *International Journal of Molecular Sciences*, 24(1), 787.
- Natesan, Vijayakumar, and Sung Jin Kim. 2023. “The Trend of Organic Based Nanoparticles in the Treatment of Diabetes and Its Perspectives.” *Biomolecules and Therapeutics*, 31(1):16–26.
- Negrescu, Andreea Mariana, Manuela S. Killian, Swathi N. V. Raghu, Patrik Schmuki, Anca Mazare, and Anisoara Cimpean. 2022. “Metal Oxide Nanoparticles: Review of Synthesis, Characterization and Biological Effects.” *Journal of Functional Biomaterials*, 13(4), 274.
- Nel, André E. 2020. “Transformational Impact of Nanomedicine: Reconciling Outcome with Promise.” *Nano Letters*, 20(8):5601–3. doi: 10.1021/acs.nanolett.0c02738.
- Ojo, Oluwafemi Adeleke, Israel Idowu Olayide, Maureen Chidinma Akalabu, Basiru Olaitan Ajiboye, Adebola Busola Ojo, Babatunji Emmanuel Oyinloye, and Murugan Ramalingam. 2021. “Nanoparticles and Their Biomedical Applications.” *Biointerface Research in Applied Chemistry*, 11(1):8431–45. doi: 10.33263/BRIAC111.84318445.
- Park, Haesun, Andrew Otte, and Kinam Park. 2022. “Evolution of Drug Delivery Systems: From 1950 to 2020 and Beyond.” *Journal of Controlled Release*, 342:53–65. doi: 10.1016/j.jconrel.2021.12.030.
- Park, Wooram, Heejun Shin, Bogyu Choi, Won Kyu Rhim, Kun Na, and Dong Keun Han. 2020. “Advanced Hybrid Nanomaterials for Biomedical Applications.” *Progress in Materials Science*, 114, 100686.
- Parsian, Hadi, Ali Rahimpour, Mohammad Nouri, Mohammad Hossein Somi, Durdi Qujeq, Mehrdad Kashi Fard, and Karim Agcheli. 2010. “Serum Hyaluronic Acid and Laminin as Biomarkers in Liver Fibrosis”. *J Gastrointestin Liver Dis*, 19(2), 169-74.
- Patel, Vrunda. 2020. “Patel V, Liposome: A Novel Carrier for Targeting Drug Delivery System.” *Asian Journal of Pharmaceutical Research and Development*, 8(4):67–76. doi: 10.22270/ajprd.v8i4.802.
- Pathak, Chandramani, Foram U. Vaidya, and Shashibhal M. Pandey. 2019. “Mechanism for Development of Nanobased Drug Delivery System.” *Applications of Targeted Nano Drugs and Delivery Systems: Nanoscience and Nanotechnology in Drug Delivery*, 35–67. doi: 10.1016/B978-0-12-814029-1.00003-X.
- Peng, Wei, Shumin Cheng, Zhihang Bao, Youjing Wang, Wei Zhou, Junxian Wang,

- Qingling Yang, Changjie hen, and Wenrui Wang. 2021. "Advances in the Research of Nanodrug Delivery System for Targeted Treatment of Liver Fibrosis." *Biomedicine & Pharmacotherapy*, 1(111342):137–46.
- Peng, Ying, Mingyue Ao, Baohua Dong, Yunxiu Jiang, Lingying Yu, Zhimin Chen, Changjiang Hu, and Runchun Xu. 2021. "Anti-Inflammatory Effects of Curcumin in the Inflammatory Diseases: Status, Limitations and Countermeasures." *Drug Design, Development and Therapy*, 15:4503–25.
- Perera, W. P. T. D., Ranga K. Dissanayake, U. I. Ranatunga, N. M. Hettiarachchi, K. D. C. Perera, Janitha M. Unagolla, R. T. De Silva, and L. R. Pahalagedara. 2020. "Curcumin Loaded Zinc Oxide Nanoparticles for Activity-Enhanced Antibacterial and Anticancer Applications." *RSC Advances*, 10(51):30785–95. doi: 10.1039/d0ra05755j.
- Plaza-Oliver, María, Manuel Jesús Santander-Ortega, and María Victoria Lozano. 2021. "Current Approaches in Lipid-Based Nanocarriers for Oral Drug Delivery." *Drug Delivery and Translational Research*, 11(2):471–97. doi: 10.1007/s13346-021-00908-7.
- Poon, Wing Lam, Jetty Chung Yung Lee, Kin Sum Leung, Harri Alenius, Hani El-Nezami, and Piia Karisola. 2020. "Nanosized Silver, but Not Titanium Dioxide or Zinc Oxide, Enhances Oxidative Stress and Inflammatory Response by Inducing 5-HETE Activation in THP-1 Cells." *Nanotoxicology*, 14(4):453–67. doi: 10.1080/17435390.2019.1687776.
- Pop, D. D. Zugravu, D. R. Mitrea, S. Suci, and S. V. Clichici. 2020. "Nanostructure-Based Therapies for Liver Fibrosis." *Journal of Physiology and Pharmacology*, 71(6), 1. doi: 10.26402/jpp.2020.6.01.
- Pote, Ajinkya Kailas, Vishal Vijay Pande, Vipul Pralhadbhai Patel, Mahendra Ashok Giri, Rasika D. Bhalke, and Aniket Uttam Pund. 2022. "Design & Development of Curcumin Loaded Zinc Oxide Nanoparticles Decorated Mesoporous Silica Liquid Stitches: A Proof of Concept in Animals." *Materials Technology*, 37(8):511–24. doi: 10.1080/10667857.2020.1863557.
- Pourmohammad, Pirouz, Reza Alipanah-Moghadam, Ali Nemati, Vadoud Malekzadeh, and Yavar Mahmoodzadeh. 2021. "Comparison of the Effects of Zinc Oxide and Zinc Oxide Nanoparticles on the Expression of Hepcidin Gene in Rat Liver." *Hormone Molecular Biology and Clinical Investigation*, 42(1):43–48. doi: 10.1515/hmbci-2020-0038.
- Prasad, Sahdeo, Dan Dubourdieu, Ajay Srivastava, Prafulla Kumar, and Rajiv Lall. 2021. "Metal–Curcumin Complexes in Therapeutics: An Approach to Enhance Pharmacological Effects of Curcumin." *International Journal of Molecular Sciences*, 22(13), 7094.
- Prasad, Sahdeo, and Rajiv Lall. 2022. "Zinc-Curcumin Based Complexes in Health and Diseases: An Approach in Chemopreventive and Therapeutic Improvement." *Journal of Trace Elements in Medicine and Biology*, 73:127023. Doi: 10.1016/J.JTEMB.2022.127023.
- Radwan, Shaimaa Ali Ali, Walaa H. El-Maadawy, Aliaa Nabil ElMeshad, Raguia Aly Shoukri, and Carol Yousry. 2020. "Impact of Reverse Micelle Loaded Lipid Nanocapsules on the Delivery of Gallic Acid into Activated Hepatic Stellate Cells: A Promising Therapeutic Approach for Hepatic Fibrosis." *Pharmaceutical Research*, 37(9), 1-17 .doi: 10.1007/s11095-020-02891-z.
- Rahman, Mahbuba. 2023. "Magnetic Resonance Imaging and Iron-Oxide Nanoparticles in the Era of Personalized Medicine." *Nanotheranostics*, 7(4):424–49.
- Rajeshkumar, S., and D. Sandhiya. 2020. "Biomedical Applications of Zinc Oxide Nanoparticles Synthesized Using Eco-Friendly Method." Pp. 65–93 in *Nanoparticles and their Biomedical Applications*. Springer Singapore.
- Ramos-Tovar, Erika, and Pablo Muriel. 2020. "Molecular Mechanisms That Link Oxidative Stress, Inflammation, and Fibrosis in the Liver." *Antioxidants*, 9(12):1–21.
- Ribera, Jordi, Clara Vilches, Vanesa Sanz, Ignacio De Miguel, Irene Portolés, Bernat Córdoba-Jover, Esther Prat, Virginia Nunes, Wladimiro Jiménez, Romain Quidant, and Manuel Morales-Ruiz. 2021. "Treatment of Hepatic Fibrosis in Mice Based on Targeted Plasmonic Hyperthermia." *ACS Nano*, 15(4):7547–62. doi: 10.1021/

- acsnano.1c00988.
- Ruman, Umme, Sharida Fakurazi, Mas Jaffri Masarudin, and Mohd Zobir Hussein. 2020. "Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities." *International Journal of Nanomedicine*, 15:1437–56. doi: 10.2147/IJN.S236927.
- Saadh, Mohamed J. 2021. "Useful Herbs for the Liver Disease Treatment." *Archives*, 3:2046–51.
- Salama, Basma, Khalid J. Alzahrani, Khalid S. Alghamdi, Osama Al-Amer, Khalid E. Hassan, Mohamed A. Elhefny, Alaa Albarakati, Fahad Alharthi, Hussam A. Althaga, Hassan Al Sberi, Hatem K. Amin, Maha S. Lokman, Khalaf F. Alsharif, Ashraf Albrakati, Ahmed E. Abdel Moneim, and Rami B. Kassab. n.d. "Silver Nanoparticles Enhance Oxidative Stress, Inflammation, and Apoptosis in Liver and Kidney Tissues: Potential Protective Role of Thymoquinone." doi: 10.21203/rs.3.rs-1828575/v1.
- Salimi, Ali, Nejat Kheiripour, Ali Fathi Jouzdani, Hassan Ghasemi, Sara Soleimani Asl, Abolfazl Ghafouri-Khosrowshahi, and Akram Ranjbar. 2022. "Nanocurcumin Improves Lipid Status, Oxidative Stress, and Function of the Liver in Aluminium Phosphide-Induced Toxicity: Cellular and Molecular Mechanisms." *BioMed Research International*, 2022(1), 7659765. doi: 10.1155/2022/7659765.
- Sameem, Shahnawaz, Netra Prasad Neupane, Saif Md Saleh Ansari, Mohd Masih Uzzaman Khan, Vikas Kumar, Prateek Pathak, Maria Grishina, and Amita Verma. 2022. "Phyto-Fabrication of Silver Nanoparticles from *Ziziphus Mauritiana* against Hepatic Carcinoma via Modulation of Rho Family-Alpha Serine/Threonine Protein Kinase." *Journal of Drug Delivery Science and Technology*, 70:103227. Doi: 10.1016/J.JDDST.2022.103227.
- Saraswathy, Ariya, Shaiju S. Nazeer, Nirmala Nimi, Hema Santhakumar, Parvathy Radhakrishnapillai Suma, Kunnumpurathu Jibin, Marina Victor, Francis Boniface Fernandez, Sabareeswaran Arumugam, Sachin J. Shenoy, P. R. Harikrishna Varma, and Ramapurath S. Jayasree. 2021. "Asialoglycoprotein Receptor Targeted Optical and Magnetic Resonance Imaging and Therapy of Liver Fibrosis Using Pullulan Stabilized Multi-Functional Iron Oxide Nanoprobe." *Scientific Reports*, 11(1). 18324. doi: 10.1038/s41598-021-97808-0.
- Sargazi, Saman, Mahtab Ghasemi Toudeshkchouei, Abbas Rahdar, Aisha Rauf, Soheil Amani, Muhammad Bilal, Razieh Behzadmehr, Ana M. Díez-Pascual, and Francesco Baino. 2023. "Emerging Nano-Theranostic Strategies against Non-Alcoholic Fatty Liver Disease: A Review." *Iranian Journal of Materials Science and Engineering*, 20(1),1.
- Sehl, Olivia C., Julia J. Gevaert, Kierstin P. Melo, Natasha N. Knier, and Paula J. Foster. 2020. "A Perspective on Cell Tracking with Magnetic Particle Imaging." *Tomography*, 6(4):315–24. doi: 10.18383/j.tom.2020.00043.
- Setyawati, Damai Ria, Fransiska Christydira Sekaringtyas, Riyona Desvy Pratiwi, A'liyatur Rosyidah, Rohimmahtunnissa Azhar, Nunik Gustini, Gita Syahputra, Idah Rosidah, Etik Mardiyati, Tarwadi, and Sjaikhurrizal El Muttaqien. 2024. "Recent Updates in Applications of Nanomedicine for the Treatment of Hepatic Fibrosis." *Beilstein Journal of Nanotechnology*, 15:1105–16. doi: 10.3762/bjnano.15.89.
- Sharma, H., Sjs Flora, A. Panghal, and S. Naqvi. 2019. "Nanomedicine: A New Therapeutic Approach in Liver Diseases." *Austin J Nanomed Nanotechnol*, 7(1). 1053.
- Shehata, Asmaa M., Fatma M. S. Salem, Eiman M. El-Saied, Sahar S. Abd El-Rahman, Mohamed Y. Mahmoud, and Peter A. Noshay. 2022. "Evaluation of the Ameliorative Effect of Zinc Nanoparticles against Silver Nanoparticle-Induced Toxicity in Liver and Kidney of Rats." *Biological Trace Element Research*, 200(3):1201–11. doi: 10.1007/s12011-021-02713-2.
- Singh, Neelu, Monoj Kumar Das, Anand Ramteke, and Paulraj R. 2020. "Oxidative Stress Mediated Hepatotoxicity Induced by ZNP and Modulatory Role of Fruit Extract on Male Wistar Rat." *Toxicology Reports*, 7:492–500. doi: 10.1016/j.toxrep.2020.03.009.
- Singh, Sukhbir, Neelam Sharma, Saurabh Shukla, Tapan Behl, Sumeet Gupta, Md Khalid Anwer, Celia Vargas-De-La-Cruz, Simona Gabriela Bungau, and Cristina Brisc.

2023. "Understanding the Potential Role of Nanotechnology in Liver Fibrosis: A Paradigm in Therapeutics." *Molecules*, 28(6), 2811.
- Smirnova, Elena, Mohammad Moniruzzaman, Sungyeon Chin, Anjana Sureshababu, Adhimoolam Karthikeyan, Kyoungtag Do, and Taesun Min. 2023. "A Review of the Role of Curcumin in Metal Induced Toxicity." *Antioxidants* 12(2).
- Somu, Prathap, and Subhankar Paul. 2019. "A Biomolecule-Assisted One-Pot Synthesis of Zinc Oxide Nanoparticles and Its Bioconjugate with Curcumin for Potential Multifaceted Therapeutic Applications." *New Journal of Chemistry*, 43(30):11934–48. doi: 10.1039/c9nj02501d.
- Spagnolo, Paolo, Oliver Distler, Christopher J. Ryerson, Argyris Tzouveleakis, Joyce S. Lee, Francesco Bonella, Demosthenes Bouros, Anna Maria Hoffmann-Vold, Bruno Crestani, and Eric L. Matteson. 2021. "Mechanisms of Progressive Fibrosis in Connective Tissue Disease (CTD)-Associated Interstitial Lung Diseases (ILDs)." *Annals of the Rheumatic Diseases*, 80(2):143–50.
- Sportelli, Maria Chiara, Caterina Gaudiuso, Annalisa Volpe, Margherita Izzi, Rosaria Anna Picca, Antonio Ancona, and Nicola Cioffi. 2022. "Biogenic Synthesis of ZnO Nanoparticles and Their Application as Bioactive Agents: A Critical Overview." *Reactions*, 3(3):423–41. doi: 10.3390/reactions3030030.
- Sun, Xiao Hui, He Zhang, Xiao Ping Fan, and Zhao Hui Wang. 2021. "Astilbin Protects against Carbon Tetrachloride-Induced Liver Fibrosis in Rats." *Pharmacology*, 106(5–6):323–31. doi: 10.1159/000514594.
- Surendran, Suchithra Poilil, Reju George Thomas, Myeong Ju Moon, and Yong Yeon Jeong. 2017. "Nanoparticles for the Treatment of Liver Fibrosis." *International Journal of Nanomedicine*, 12:6997–7006.
- Swarupananda, Mukherjee, Dutta Ayon, and Ash Dipanjana. 2021. "Lipid Nanoparticulate Drug Delivery System for the Treatment of Hepatic Fibrosis." *Archives of Hepatitis Research*, 001–003. doi: 10.17352/ahr.000028.
- Tan, Chen, Jing Wang, and Baoguo Sun. 2021. "Biopolymer-Liposome Hybrid Systems for Controlled Delivery of Bioactive Compounds: Recent Advances." *Biotechnology Advances*, 48:107727. Doi: 10.1016/J.BIOTECHADV.2021.107727.
- Tan, Zui, Hongbao Sun, Taixiong Xue, Cailing Gan, Hongyao Liu, Yuting Xie, Yuqin Yao, and Tinghong Ye. 2021. "Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy." *Frontiers in Cell and Developmental Biology*, 9, 730176.
- Teng, Chao, Bingbing Li, Chenshi Lin, Xuyang Xing, Feifei Huang, Yi Yang, Yi Li, Helena S. Azevedo, and Wei He. 2022. "Targeted Delivery of Baicalein-P53 Complex to Smooth Muscle Cells Reverses Pulmonary Hypertension." *Journal of Controlled Release*, 341:591–604. doi: 10.1016/J.JCONREL.2021.12.006.
- Teng, Wendi, Liyun Zhao, Songtao Yang, Chengying Zhang, Meiyu Liu, Jie Luo, Junhua Jin, Ming Zhang, Chen Bao, Dan Li, Wei Xiong, Yuan Li, and Fazheng Ren. 2019. "The Hepatic-Targeted, Resveratrol Loaded Nanoparticles for Relief of High Fat Diet-Induced Nonalcoholic Fatty Liver Disease." *Journal of Controlled Release*, 307:139–49. doi: 10.1016/j.jconrel.2019.06.023.
- Thapa, Raj Kumar, and Jong Oh Kim. 2023. "Nanomedicine-Based Commercial Formulations: Current Developments and Future Prospects." *Journal of Pharmaceutical Investigation*, 53(1):19–33.
- Thorp, Edward B., Christian Boada, Clarens Jarbath, and Xunrong Luo. 2020. "Nanoparticle Platforms for Antigen-Specific Immune Tolerance." *Frontiers in Immunology*, 11, 945.
- Trivella, Juan P., Paul Martin, and Andres F. Carrion. 2020. "Novel Targeted Therapies for the Management of Liver Fibrosis." *Expert Opinion on Emerging Drugs* 25(1):59–70.
- Tulbah, Alaa S., and Wing Hin Lee. 2021. "Physicochemical Characteristics and in Vitro Toxicity/Anti-Sars-Cov-2 Activity of Favipiravir Solid Lipid Nanoparticles (SLNs)." *Pharmaceuticals*, 14(10), 1059. doi: 10.3390/ph14101059.
- Ugo, Lorenzo, Silvia Brocco, Arcangelo Merola, Claudia Mescoli, and Emilio Quaia. 2021. "Liver Anatomy." Pp. 15–47 in *Medical Radiology*. Springer Science and Business Media Deutschland GmbH.
- Urushima, Hayato, Hideto Yuasa, Tsutomu Matsubara, Noriyuki Kuroda, Yaiko Hara,

- Kouji Inoue, Kenjiro Wake, Tetsuji Sato, Scott L. Friedman, and Kazuo Ikeda. 2021. "Activation of Hepatic Stellate Cells Requires Dissociation of E-Cadherin–Containing Adherens Junctions with Hepatocytes." *American Journal of Pathology*, 191(3):438–53. doi: 10.1016/j.ajpath.2020.12.007.
- Vakil, Vahideh, and Wade Trappe. 2019. "Drug Combinations: Mathematical Modeling and Networking Methods." *Pharmaceutics*, 11(5). 208.
- Vuppalanchi, Raj, Mazen Nouredin, Naim Alkhouri, and Arun J. Sanyal. 2021. "Therapeutic Pipeline in Nonalcoholic Steatohepatitis." *Nature Reviews Gastroenterology and Hepatology* 18(6):373–92.
- Wang, Hairui, and Yongzhuo Huang. 2020. "Combination Therapy Based on Nano Codelivery for Overcoming Cancer Drug Resistance." *Medicine in Drug Discovery*, 6:100024. Doi: 10.1016/J.MEDIDD.2020.100024.
- Wang, Jingyu, Wenling Zhao, Zhao Zhang, Xingzi Liu, Tong Xie, Lan Wang, Yuzhou Xue, and Yuemiao Zhang. 2024. "A Journey of Challenges and Victories: A Bibliometric Worldview of Nanomedicine since the 21st Century." *Advanced Materials*, 36(15), 2308915. Doi: 10.1002/adma.202308915.
- Wang, Ruyi, Zhongtao Zhang, Bowen Liu, Jingwei Xue, Fulei Liu, Tongzhong Tang, Wenyan Liu, Feng Feng, and Wei Qu. 2021. "Strategies for the Design of Nanoparticles: Starting with Long-Circulating Nanoparticles, from Lab to Clinic." *Biomaterials Science*, 9(10):3621–37.
- Wang, Shuang, Kenneth Li, Eliana Pickholz, Ross Dobie, Kylie P. Matchett, Neil C. Henderson, Chris Carrico, Ian Driver, Martin Borch Jensen, Li Chen, Mathieu Petitjean, Dipankar Bhattacharya, Maria I. Fiel, Xiao Liu, Tatiana Kisseleva, Uri Alon, Miri Adler, Ruslan Medzhitov, and Scott L. Friedman. 2023. "An Autocrine Signaling Circuit in Hepatic Stellate Cells Underlies Advanced Fibrosis in Nonalcoholic Steatohepatitis". *Science translational medicine*, 15(677), eadd3949.
- Wang, Xiaolin, Yong He, Bryan MacKowiak, and Bin Gao. 2021. "MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in Liver Diseases." *Gut*, 70(4):784–95. doi: 10.1136/gutjnl-2020-322526.
- Wiering, Leke, Pallavi Subramanian, and Linda Hammerich. 2023. "Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease." *CMGH*, 15(6):1277–92.
- Wu, Lei, Wenhui Zhou, Lihua Lin, Anhong Chen, Jing Feng, Xiangmeng Qu, Hongbo Zhang, and Jun Yue. 2022. "Delivery of Therapeutic Oligonucleotides in Nanoscale." *Bioactive Materials*, 7:292–323.
- Xia, Shenglong, Zimo Liu, Jieru Cai, Huiming Ren, Qi Li, Hongfang Zhang, Jing Yue, Quan Zhou, Tianhua Zhou, Liangjing Wang, Xiangrui Liu, and Xuefei Zhou. 2023. "Liver Fibrosis Therapy Based on Biomimetic Nanoparticles Which Deplete Activated Hepatic Stellate Cells." *Journal of Controlled Release*, 355:54–67. doi: 10.1016/J.JCONREL.2023.01.052.
- Xiao, Qingqing, Xiao Zhu, Yuting Yuan, Lifang Yin, and Wei He. 2018. "A Drug-Delivering-Drug Strategy for Combined Treatment of Metastatic Breast Cancer." *Nanomedicine: Nanotechnology, Biology, and Medicine*, 14(8):2678–88. doi: 10.1016/j.nano.2018.06.012.
- Xing, Lei, Xin Chang, Lijun Shen, Chenglu Zhang, Yatong Fan, Chongsu Cho, Zhiqi Zhang, and Hulin Jiang. 2021. "Progress in Drug Delivery System for Fibrosis Therapy." *Asian Journal of Pharmaceutical Sciences*, 16(1):47–61.
- Xu, Hongjiao, Qian Zhao, Nazi Song, Zhibin Yan, Runfeng Lin, Shuohan Wu, Lili Jiang, Sihua Hong, Junqiu Xie, Huihao Zhou, Rui Wang, and Xianxing Jiang. 2020. "AdipoR1/AdipoR2 Dual Agonist Recovers Nonalcoholic Steatohepatitis and Related Fibrosis via Endoplasmic Reticulum-Mitochondria Axis." *Nature Communications*, 11(1), 5807. doi: 10.1038/s41467-020-19668-y.
- Yin, Lichen, and Zhiyuan Zhong. 2020. "Nanoparticles." *Biomaterials Science: An Introduction to Materials in Medicine*, 453–83. doi: 10.1016/B978-0-12-816137-1.00031-3.
- Younis, Mahmoud A., Ikramy A. Khalil, Yaser H. A. Elewa, Yasuhiro Kon, and Hideyoshi Harashima. 2021. "Ultra-Small Lipid Nanoparticles Encapsulating Sorafenib and Midkine-SiRNA Selectively-Eradicate Sorafenib-Resistant Hepatocellular Carcinoma in Vivo." *Journal of Controlled Release*, 331:335–49. doi: 10.1016/j.

- jconrel.2021.01.021.
- Yuan, Shoujun, and Haoyu Chen. 2019. "Mathematical Rules for Synergistic, Additive, and Antagonistic Effects of Multi-Drug Combinations and Their Application in Research and Development of Combinatorial Drugs and Special Medical Food Combinations." *Food Science and Human Wellness*, 8(2):136–41. doi: 10.1016/J.FSHW. 2019.01.003.
- Yuasa, Hideto, Tsutomu Matsubara, Hayato Urushima, and Kazuo Ikeda. 2024. "The Unique Architecture of the Hepatic Sinusoid." *Sinusoidal Cells in Liver Diseases: Role in Their Pathophysiology, Diagnosis, and Treatment*, 3–22. doi: 10.1016/B978-0-323-95262-0.00001-2.
- Zahin, Nuzhat, Raihanatul Anwar, Devesh Tewari, Md Tanvir Kabir, Amin Sajid, Bijo Mathew, Md Sahab Uddin, Lotfi Aleya, and Mohamed M. Abdel-Daim. 2020. "Nanoparticles and Its Biomedical Applications in Health and Diseases: Special Focus on Drug Delivery." *Environmental Science and Pollution Research*, 27(16):19151–68. doi: 10.1007/s11356-019-05211-0.
- Zapotoczny, Bartłomiej, Karolina Szafranska, Edyta Kus, Filip Braet, Eddie Wisse, Stefan Chłopicki, and Marek Szymonski. 2019. "Tracking Fenestrae Dynamics in Live Murine Liver Sinusoidal Endothelial Cells." *Hepatology*, 69(2). doi: 10.1002/hep.30232/supinfo.
- Zhang, Chao, and Chuanbao Zhang. 2022. "Analysis of Current Status of Quantitative Detection of Biomarkers for Liver Fibrosis in Clinical Labs in China." *Journal of Clinical Laboratory Analysis*, 36(7). doi: 10.1002/jcla.24490.
- Zhang, Chenyang, Liang Yan, Xin Wang, Shuang Zhu, Chunying Chen, Zhanjun Gu, and Yuliang Zhao. 2020. "Progress, Challenges, and Future of Nanomedicine." *Nano Today*, 35, 101008.
- Zhang, Chi, Jiang Zhao, Weihao Wang, Huanhuan Geng, Yinzhe Wang, and Baoshan Gao. 2023. "Current Advances in the Application of Nanomedicine in Bladder Cancer." *Biomedicine and Pharmacotherapy*, 157, 114062.
- Zhang, Hongru, Joe Antony Jacob, Ziyu Jiang, Senlei Xu, Ke Sun, Zehao Zhong, Nithya Varadharaju, and Achiraman Shanmugam. 2019. "Hepatoprotective Effect of Silver Nanoparticles Synthesized Using Aqueous Leaf Extract of *Rhizophora Apiculata*." *International Journal of Nanomedicine*, 14:3517–24. doi: 10.2147/IJN.S198895.
- Zhang, Ling Feng, Wen Qi Deng, Qing Wen Huang, Jiao Jiao Zhang, Yi Wang, Tian Jiao Zhou, Lei Xing, and Hu Lin Jiang. 2024. "Vicious Cycle-Breaking Lipid Nanoparticles Remodeling Multicellular Crosstalk to Reverse Liver Fibrosis." *Advanced Materials*, 36(16), 2311474. Doi: 10.1002/adma.202311474.
- Zhang, Sainan, Wenqian Chen, and Chunxia Zhu. 2020. "Liver Structure." Pp. 21–47 in *Artificial Liver*. Springer Singapore.
- Zhang, Wunan, Roland Böttger, Zhu Qin, Jayesh A. Kulkarni, Julian Vogler, Pieter R. Cullis, and Shyh Dar Li. 2019. "Phospholipid-Free Small Unilamellar Vesicles for Drug Targeting to Cells in the Liver." *Small*, 15(43), 1901782. doi: 10.1002/smll.201901782.
- Zhao, Xingtao, Felix Kwame Amevor, Xinyan Xue, Cheng Wang, Zhifu Cui, Shu Dai, Cheng Peng, and Yunxia Li. 2023. "Remodeling the Hepatic Fibrotic Microenvironment with Emerging Nanotherapeutics: A Comprehensive Review." *Journal of Nanobiotechnology*, 21(1). 121.
- Zhu, Meilin, Hanqing Chen, Shuang Zhou, Lingna Zheng, Xue Li, Runxuan Chu, Wei Chen, Bing Wang, Meng Wang, Zhifang Chai, and Weiyue Feng. 2021. "Iron Oxide Nanoparticles Aggravate Hepatic Steatosis and Liver Injury in Nonalcoholic Fatty Liver Disease through BMP-SMAD-Mediated Hepatic Iron Overload." *Nanotoxicology*, 15(6):761–78. doi: 10.1080/17435390.2021.1919329.
- Ziaolhagh, Sayyed Javad, Malihe Ardakanizadeh, Armin Kaveh, and Behrooz Yahyaei. 2023. "Liver Tissue Changes Induced by Biological and Chemical Silver Nanoparticles in Trained Male Wistar Rats." *Journal of Trace Elements in Medicine and Biology*, 79:127253. Doi: 10.1016/J.JTEMB.2023.127253.
- Zielinska, Aleksandra, Filipa Carreiró, Ana M. Oliveira, Andreia Neves, Bárbara Pires, D. Nagasamy Venkatesh, Alessandra Durazzo, Massimo Lucarini, Piotr Eder, Amélia

M. Silva, Antonello Santini, and Eliana B. Souto. 2020. "Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology." *Molecules*, 25(16). 121